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Resumo A terapia fotodinâmica (PhotodynamicTherapy, PDT) é uma metodologia emergente no 
tratamento de diversas doenças oncológicas e tem por base o uso de oxigénio molecular, 
luz e um fotossensibilizador (FS) para seletivamente destruir as células tumorais. Em 
oncologia, a PDT leva à indução de espécies reativas de oxigénio (reactive oxygen species, 
ROS) no tecido tumoral, no qual ocorreu previamente o uptake preferencial e/ou a retenção 
de um FS. 
  As ftalocianinas têm-se vindo a revelar FSs promissores na PDT devido às suas 
propriedades foto-físicas. Contudo, estes compostos para além de pouco solúveis em água, 
têm problemas de agregação e de especificidade para os tecidos tumorais. Assim, o trabalho 
apresentado nesta tese teve como objetivo principal conjugar co-axialmente ftalocianinas 
de silício (silicon phthalocyanines, SiPcs) com duas moléculas de galactose (SiPcGal2) e 
com duas unidades dendríticas de galactose (SiPcGal4) para que estes FSs fossem 
reconhecidos por galectinas (e.g. galectina-1) sobrexpressas em células tumorais. Contudo, 
os compostos desejados finais não foram obtidos, uma vez que a remoção dos grupos 
isopropilideno, protetores dos grupos hidroxilo das unidades de galactose, não foi 
conseguida. Assim, foram avaliadas as propriedades foto-físicas e foto-químicas das SiPcs 
com as galactoses protegidas, comparando com a SiPc dihidróxido (SiPc(OH)2), de forma 
a estudar a influência da conjugação co-axial de biomoléculas no core destes tipo de FSs. 
Infelizmente, a solubilidade das SiPcs em solventes aquosos não foi conseguida, contudo o 
seu espectro de absorção UV-visível evidenciou elevada absorção a altos comprimentos de 
onda (650-700 nm), janela espectrofotométrica onde ocorre uma penetração mais profunda 
da luz nos tecidos. Para além disso, estes FSs demonstraram-se excelentes marcadores 
fluorescentes, estáveis após irradiação e bons geradores de 1O2. Foram ainda realizados 
estudos in vitro com o objetivo de validar o seu potencial fotodinâmico no tratamento do 
cancro da bexiga, sendo que a SiPcGal4 e a SiPcGal2 agregaram nas células, tendo assim 
um baixo uptake, baixa toxicidade após foto-ativação e baixa produção de ROS.  
  No geral, as SiPcs demonstraram um grande potencial como futuros FSs para a PDT, dado 
as suas excelentes propriedades foto-físicas, o que nos incentiva na descoberta de novas 
técnicas que diminuam a sua agregação nas células, como a utilização de bio-formulações 
estáveis e a desproteção das moléculas de galactose, que também irá aumentar a sua 
especificidade para células tumorais. 
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Abstract Photodynamic Therapy (PDT) relies on the combination of a photosensitizer (PS), light and 
molecular oxygen (O2) to generate reactive oxygen species (ROS), which can trigger cell 
death pathways. In oncology, the PS needs to be preferentially accumulated in cancer cells 
and a good generator of ROS (especially singlet oxygen, 1O2).  
Phthalocyanines (Pcs) are promising PSs in PDT due to their photochemical and 
photophysical properties. However, Pcs present solubility and aggregation problems, as well 
as low selectivity to the cancer tissue. Therefore, it will be conjugated a silicon 
phthalocyanine (SiPc) with two galactose molecules (SiPcGal2) and another with two 
galacto-dendritic units (SiPcGal4), both in axial positions. The aim of that conjugation is to 
promote the binding of the PS with galactose-binding proteins such as galectins (e.g. 
galectin-1) which are found to be overexpressed in cancer cells. Nevertheless, the desired 
compound were not obtained, once the hydrolysis of the isopropylidene galactose-protective 
groups didn’t work. Thereby, the photophysical and photochemical properties of those two 
SiPcs with the galactose-protective groups were studied in comparison with the SiPc 
dihydroxide (SiPc(OH)2), in order to study the SiPc core properties as well as the influence 
of an axial conjugation of biomolecules. The PSs solubility was compromised in an aqueous 
solution, however their absorption UV-Visible spectra showed high absorption peaks at a 
high wavelengths range (650–700 nm), which is the ideal therapeutical window where there 
is a higher penetration of light into the tissues. Furthermore, these SiPcs demonstrated to be 
good fluorescence labels, photostable and good 1O2 generators. In vitro studies were 
performed with the aim of validating them as photodynamic therapeutic agents against 
bladder cancer cells, however SiPcGal4 and SiPcGal2 aggregated on cells, having a low 
uptake, phototoxicity and ROS production. 
Overall, SiPcs have demonstrated a great potential as future PSs for PDT, thanks to their 
excellent photophysical properties, which prompt us in the discovery of different approaches 
that diminished their aggregation on cells, such as the incorporation of PSs into bio-stable 
formulations and the deprotection of the galactose molecules, which will also increase their 
specificity to tumoral cells. 
 
viii 
 
Contents 
 
Resumo  ................................................................................................................. vi 
Abstract  ................................................................................................................ vii 
Abbreviations and acronyms ................................................................................. xii 
 
CHAPTER I - Introduction .................................................................................... 1 
1. Overview ........................................................................................................... 3 
2. Photodynamic therapy ....................................................................................... 4 
2.1 Brief History .................................................................................................. 4 
2.2 Molecular basis of PDT ................................................................................ 5 
3. Photosensitizers ................................................................................................ 7 
4. Phthalocyanines .............................................................................................. 13 
4.1 Silicon Phthalocyanines ............................................................................. 15 
4.2 Phthalocyanines galacto-dendritic conjugates ........................................... 16 
5. Photodynamic therapy in clinical applications ................................................. 19 
5.1 Bladder Cancer .......................................................................................... 20 
6. Objectives and working plan ........................................................................... 26 
 
CHAPTER II - Results and Discussion ............................................................. 29 
1. Novel galacto-conjugated silicon phthalocyanines: synthesis and 
characterization ............................................................................................... 32 
1.1 Overview .................................................................................................... 32 
1.2 Synthesis of galacto-dendritic units ............................................................ 33 
1.3 Synthesis of galacto-conjugated silicon phthalocyanines ........................... 36 
ix 
 
1.3.1 Synthesis of a symmetrical silicon phthalocyanine axial 
conjugated with galactose moieties [4] ................................................... 36 
1.3.2 Synthesis of a symmetrical silicon phthalocyanine axially 
conjugated with compound 2 [5] ............................................................. 38 
1.3.3 Synthesis of a symmetrical silicon phthalocyanine axially 
conjugated with compound 3 [6] ............................................................. 38 
2. Photophysical and photochemical studies of galacto-conjugates .................... 44 
2.1 UV-Visible characterization, water solubility and fluorescence emission .... 44 
2.2 Singlet oxygen production .......................................................................... 48 
2.3 Photostability of the galacto-conjugates ..................................................... 49 
3. In vitro studies of the galacto-conjugates ........................................................ 52 
3.1 Overview .................................................................................................... 52 
3.2 Uptake of galacto-conjugates by UM-UC-3 bladder cancer cells ............... 53 
3.3 Dark toxicity and phototoxicity determination of galacto-conjugates in UM-UC-
3 bladder cancer cells ................................................................................ 56 
3.4 SiPcGal4, SiPcGal2 and SiPc(OH)2 induced reactive oxygen species 
production after PDT in UM-UC-3 bladder cancer cells .............................. 59 
 
CHAPTER III - Conclusion and future perspectives ........................................ 61 
 
CHAPTER IV - Methods and Materials .............................................................. 67 
1. Synthesis of galacto-phthalocyanines ............................................................. 70 
1.1 Equipment, materials and reagents ............................................................ 70 
1.2 Experimental procedures ........................................................................... 71 
1.2.1 Galacto-dendritic units synthesis ................................................ 71 
A. Synthesis of 2-chloro-4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-
galactopyran-6-yl)-1,3,5-triazine [1] (72) .............................................. 71 
x 
 
B.  Synthesis of 3-[(4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-galactopyran-6-
yl)-1,3,5-triazin-2-yl)thio]propane-1-thiol [2] (72) .................................. 72 
C. Synthesis of 3-[(4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-galactopyran-6-
yl)-1,3,5-triazin-2-yl)oxi]propane-1-diol [3] ............................................ 72 
1.2.2 Coupling of SiPcCl2 with galacto-dendritic units ......................... 73 
A. Synthesis of SiPc 4 [SiPcGal2] (45) ..................................................... 73 
B.  Failed attempt of synthesis of SiPc 5 ................................................ 73 
C. Synthesis of SiPc 6 [SiPcGal4] ............................................................. 74 
1.2.3 Failed attempts of deprotection of the isopropylidene groups .... 74 
A. Deprotection of isopropylidene groups in SiPcGal4 and SiPcGal2 using 
TFA/water (9:1) .................................................................................... 74 
B. Deprotection of isopropylidene groups in SiPcGal4 and SiPcGal2 using 
TMSBr .................................................................................................. 75 
2. Photophysical and photochemical studies of galacto-conjugates .................... 78 
2.1 Equipment and reagents ............................................................................ 78 
2.2 Experimental procedures ........................................................................... 79 
2.2.1 Aggregation assays .................................................................... 79 
2.2.2 Fluorescence emission assay .................................................... 79 
2.2.3 Photostability assays .................................................................. 80 
2.2.4 Singlet oxygen assays ............................................................... 80 
3. In vitro biological studies ................................................................................. 84 
3.1 Equipment, materials and reagents ............................................................ 84 
3.2 Experimental procedures ........................................................................... 86 
3.2.1 Cell culture and subculture ......................................................... 86 
3.2.2 Preparation and treatment of UM-UC-3 cells with photosensitizers 
   ................................................................................................... 87 
3.2.3 Determination of intracellular PS concentration by fluorimetry ... 88 
xi 
 
A. Determination of intracellular PS fluorescence ..................................... 88 
B. Determination of protein concentration ................................................. 89 
3.2.4 Determination of intracellular PS fluorescence by fluorescence 
microscopy ............................................................................................. 90 
3.2.5 Photodynamic Assays ................................................................ 90 
3.2.6 Cell viability assay ...................................................................... 90 
3.2.7 Intracellular levels of Reactive Oxygen Species after PDT ........ 91 
 
CHAPTER V - Bibliography ................................................................................ 93 
 
  
xii 
 
Abbreviations and acronyms 
 
ADME  Adsorption, distribution, metabolism and excretion 
ASR   Age standardized incidence rate 
BCG   Bacillus Calmette-Guerin 
Acridine  2,3-benzoquinoline 
BC   Bladder Cancer 
BCA   Bicinchoninic Acid 
BSA   Bovine Serum Albumin 
TMSBr  Bromotrimethylsilane 
CRD   Carbohydrate-recognition domains 
CIS   Carcinoma in situ 
ALA   Delta-aminolevulinic acid 
DAPI   4’,6-diamino-2-phenylindole 
H2DCFDA  2’,7’-dichlorohydrofluorescin 
DCM   Dichloromethane 
DHE   Dihydroethidium 
DIPEA  N,N-diisopropylethylamine 
DMF   Dimethylformamide 
DMSO  Dimethyl sulfoxide 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
DPBF   1,3-Diphenylisobenzofuran 
ESI+-MS  Electrospray ionization mass spectrometry 
EPR   Enhanced permeability and retention 
FDA   Food and Drug Administration 
Hp   Hematoporphyrin 
HpD   Hematoporphyrin Derivative 
HSA   Human Serum Albumin 
IR   Infrared 
RNAi   Interference Ribonucleic Acid 
IC   Internal Conversion 
ISC   Intersystem crossing 
IM   Intramuscular 
IV   Intravenous 
LEDs   Light Emitting Diodes 
MALDI-MS  Matrix-assisted laser desorption/ionization Mass Spectrometry 
TPP   meso-tetraphenylporphyrin 
MPcs   Metallo-phthalocyanines 
MB   Methylene Blue 
MitoPy1  Mitochondria peroxy yellow 1 
mAb   Monoclonal antibody 
xiii 
 
NMR   Nuclear magnetic resonance 
PK   Pharmacokinetics 
PBS   Phosphate-buffered saline 
P   Phosphorescence 
PAPs   Photoactive porphyrins 
PDT   Photodynamic Therapy 
PS   Photosensitizer 
Pc   Phthalocyanine 
Por   Porphyrin 
Pre-mRNA  Precursor messenger ribonucleic acid 
PpIX   Protoporphyrin IX 
ROS   Reactive Oxygen Species 
rt   Room temperature 
SiPc   Silicon phthalocyanine 
SDS   Sodium dodecyl sulfate 
SC   Subcutaneous 
PFA   Paraformaldehyde 
Rose Bengal  4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein 
THF   Tetrahydrofuran 
TLC   Thin layer chromatography 
TUR   Transurethral resection 
TCT   2,4,6-trichloro-1,3,5-triazine 
TNM   Tumor-Node-Metastases 
UV/Vis  UV/Visible 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER I 
INTRODUCTION 
 
  
Introduction 
 
2 
 
Introduction 
 
3 
 
1. Overview 
  
Cancer is a disease caused by an abnormal growth of cells which tend to 
proliferate in an uncontrolled way and, in some cases, to spread out to other organs 
of the body through the blood and lymph systems. This process is named metastasis 
and corresponds to the most advanced stage of cancer and the most common 
cause of cancer death. There are more than 100 different types of cancer. In 2012, 
there were approximately 14 million of new cancer cases and 8.2 million of cancer 
related deaths (1). The most common and conventional cancer treatments are 
surgery, and/or radiotherapy, and/or chemotherapy. However, there are serious 
side effects in those treatments, such as loss of normal cell function. In order to 
counter that, less invasive approaches were developed over the years, targeted 
therapies that use drugs to more precisely identify and destroy cancer cells, causing 
far less damage to healthy cells. Photodynamic Therapy (PDT) is a newer type of 
therapeutic approach that uses special drugs named photosensitizing agents, along 
with light to induce cancer cell death, through the production of reactive oxygen 
species (ROS). PDT can be applied alone or in combination with the aforementioned 
traditional treatments (2,3). 
The pursuit of new photosensitizing agents for PDT is a lively research field. 
Those drugs should specifically accumulate in cancer tissues and have high 
production of ROS. The conjugation of galactose targeting moieties with a 
porphyrinoid-based drug is a valuable way to achieve a high local concentration of 
that drug in tumor tissues, since certain galectins (i.e. galectin-1 and galectin-3) are 
overexpressed on the target cells relatively to normal tissues (4).  
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2. Photodynamic therapy 
 
In oncology, PDT is an emerging treatment modality able to treat many forms 
of cancer and other non-neoplastic diseases (5-7), being particularly interesting in 
the tumors that occur in cavities (such as bladder, esophagus or intestine). This 
methodology combines a photosensitizer (PS) with light of appropriate wavelength 
and molecular oxygen (O2). None of these elements are toxic by themselves, 
however when combined they generate ROS that kill malignant cells by triggering a 
cascade of cytotoxic reactions (8). In order to allow that the knowledge of 
photosensitization can be rapidly applied in clinical practice, PDT requires the 
cooperation of chemists (e.g., for synthesis of new PS), biologists (e.g., for testing 
new substances), physicists (e.g., for light dosimetry), and clinicians (e.g., for the 
transfer from the lab bench to the clinical application). 
 
2.1 Brief History 
 
The first clinical use of PDT date back to 1903 when Tappeiner and Jesionek 
combined a topical application of eosin with white light to treat skin tumors, lupus 
and condylomata of female genitalia (9). After ten years, Meyer-Betz found out that 
porphyrins (Pors) act as photosensitizing agents in humans while injecting 200 mg 
of hematoporphyrin (Hp) in himself. (10). However, after sun light exposure there 
were side effects, such as severe pain and swelling confined to the light-exposed 
areas. Around the 1960’s, Schwartz and Lipson described the tumor accumulation 
of Hp derivatives (HpD, a mixture of monomers, dimers and oligomers) as well as 
their use in tumors photodetection (11). Since these pioneering works, several 
compounds have been developed and tested. Among them, there is Photofrin®, the 
first PS approved for clinical PDT in the treatment of superficial bladder cancer in 
Canada and early lung and advanced esophageal cancers in The Netherlands and 
Japan (12). Considering the ideal properties of a PS, that will be explained further 
on detail, a wide range of synthetic or natural PSs have been studied, tested in vivo 
and in vitro, and some of them are currently in advanced stages of clinical trials. 
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Examples of new PSs are synthetic Pors (13), benzoporphyrins (14), chlorins (15), 
phthalocyanines (Pcs) (16), among others. 
 
2.2 Molecular basis of PDT 
 
Photophysics 
 
PDT is based on the PS administration and after a preferential uptake and/or 
retention period the affected area is irradiated with light to induce photoreactions. 
Upon illumination with light of an appropriate wavelength, PS absorbs a photon 
leading to the formation of an electronically excited singlet state (1PS*). However, 
this short-lived species can lose their energy and restore the ground state by 
emission of fluorescence or by internal conversion (IC, non-radiative transitions 
between two electronic states with the same spin multiplicity) with energy loss as 
heat. The singlet state 1PS*, can also undergo the process known as intersystem 
crossing (ISC), leading to formation of the long-lived triplet excited state (3PS*). The 
energy of 3PS* can be dissipated (leading the PS to its ground state) through two 
main pathways: i) thermal decay, i.e. IC; or ii) by emission of light, namely 
phosphorescence (P). In Figure 1.1 it is represented a modified Jablonski diagram 
that illustrates the electronic states of the PS and the transitions between them. 3PS* 
usually has a lifetime in the microsecond range (typically > 0.5 µs), which is sufficient 
to enable interaction between the excited PS and surrounding biomolecules. 
Moreover, this state can induce cytotoxic effects by PDT through two kinds of 
reactions, defined as Type I and Type II photoreactions (17). 
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Figure 1.1 Modified Jablonsky energy diagram showing the various modes of excitation 
and relaxation occurring in PSs: excitation (E), internal conversion (IC), fluorescence (F), 
phosphorescence (P), intersystem crossing (ISC). Type I and Type II photoreactions are 
also represented. 
 
 
Photochemistry 
 
Type I photoreactions can proceed by an electron (and/or proton) transfer 
process, hence causing a direct interaction of 3PS* with the cellular substrate (lipids, 
proteins, nucleic acids, etc.) leading to generation of radicals. Subsequent reaction 
with O2 forms ROS, such as the superoxide anion (O2·⁻), the hydroxyl radical (OH·), 
and hydrogen peroxide (H2O2) that initiate radical chain reactions (18,19).  
Alternatively, Type II photoreactions proceed by energy transfer, where the 
interaction of O2 in its ground triplet state (3O2) with 3PS* generates a more reactive 
form of oxygen, i.e. singlet oxygen (1O2). This non-radical species are highly reactive 
towards electrons rich substrates such as for instance, double bonds, aromatic 
rings, amines and thioethers (18,19). They also react with plasmatic membrane 
biomolecules and different cellular organelles, leading to the selective destruction 
of the target cells by necrosis and/or apoptosis and/or autophagy-associated cell 
death, without damaging the healthy tissue (Figure 1.1). Antitumor effects of PDT 
derive from three inter-related mechanisms: direct cytotoxic effects on tumor cells, 
damage to the tumor vasculature and induction of a robust inflammatory reaction 
that can lead to the development of systemic immunity (3). The role of 1O2 in the 
photodynamic effect is controversial between researchers. However, for most PSs 
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currently under investigation, the 1O2-mediated photodynamic mechanism is the 
model of cytotoxic action usually accepted (20). To investigate the chemistry of 1O2, 
several analytical tools can be used such as spectrophotometry, fluorimetry, and 
chemiluminometry. In spectrophotometry, 1O2 react rapidly and irreversibly with a 
probe (e.g. diphenylisobenzofuran, DPBF) to initially yield an endoperoxide which, 
in turn, emerge into other products that do not fluoresce and have absorption 
spectra different from that of the probe (21). The use of selective and photo-
activated PS makes PDT a promising technique for the treatment of a variety of 
oncological diseases. 
 
3. Photosensitizers 
 
A PS, which is a molecule that enters an excited state when exposed to light 
of a specific wavelength, can use that energy to induce cytotoxic reactions leading 
to cell death and tissue destruction. Thus, a good PS agent with potentially optimal 
properties for PDT should be endowed with specific features: i) single pure 
compound; ii) low manufacturing costs and good stability in storage; iii) no dark 
toxicity, but being toxic upon photo-activation; iv) rapid clearance from normal 
tissues to minimize phototoxic side effects; v) high triplet-state quantum yields, i.e., 
triplet-state with lifetimes enough and sufficiently energetic to produce 1O2 and vi) 
high absorption peak between 600 and 800 nm (therapeutic window). This last 
characteristic is related to the aforementioned light penetration into the tissues once 
in this range the light wavelengths are still energetic enough to produce 1O2 and 
tissues are more transparent, thus light has its maximum depth of penetration 
(Figure 1.2). Absorption bands at shorter wavelengths than 600 nm have less tissue 
penetration due to the endogenous absorption by tissue cromophores (e.g. oxy-
/deoxy- hemoglobin, melanin), leading to skin photosensitivity. At wavelengths 
higher than 800 nm there is not enough energy for the 3PS* transfer to the ground 
state of O2 in order to excite it to the singlet state (20). 
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Figure 1.2. Propagation of light through the tissues. Adapted from (3). 
 
Although many PSs, such as methylene blue (3,7-bis(dimethylamino)-
phenothiazin-5-ium chloride, MB), rose bengal (4,5,6,7-tetrachloro-2',4',5',7'-
tetraiodofluorescein) and acridine (2,3-benzoquinoline) are known to be efficient 1O2 
generators, the vast majority that are successful as PDT agents are based upon the 
tetrapyrrole chromophore (22). Tetrapyrroles usually have a large absorption band 
in the region of 400 nm known as the Soret band, and a set of absorption bands as 
the spectrum gets closer to red wavelengths – known as Q bands (23). 
The evaluation of physicochemical properties of a new PS can be performed 
by spectroscopic techniques and in vitro studies can be used to highlight specific 
applications. Additionally, it is important to screen the absorption, distribution, 
metabolism and excretion (ADME) properties in order to avoid the clinical failure of 
drug candidates. According to a survey by Food and Drug Administration (FDA) in 
1991, approximately 40 % of clinical failure was due to poor pharmacokinetics (PK) 
properties (24). Then, pharmaceutical companies began assessing those properties 
of new chemical entities at the very early stages of drug discovery (25). Several 
techniques can be used for this screening, such as in vitro optimization to 
understand the specific factors that contribute to the drug disposition, and in vivo 
methods that provide more integrated means for optimizing ADME properties (26). 
300nm 400nm 500nm 600nm 
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Starting with the administration, there are three possible routes: enteral route 
(oral, where the effect is systemic and the substance is given via the digestive tract), 
parenteral route (the effect is also systemic but the substance is given by routes 
other than the digestive tract) and topical (the substance is applied directly where 
its action is desired and the effect is local). Parenteral administration routes include 
several injections types: intravenous (IV), subcutaneous (SC), intradermal and 
intramuscular (IM). Many factors affect the drug distribution (i.e. its transport from 
the point of administration or absorption to the site of action), such as the vascular 
permeability, regional blood flow, cardiac output, perfusion rate of the tissue and the 
binding ability of the drug to plasma proteins. The lipophilic drug properties that are 
desirable to its uptake into the biological membranes of its effector site are 
prejudicial to its elimination of the body. That is why it needs to be metabolized into 
more hydrophilic metabolites that will be able to pass the renal tubes without being 
reabsorbed. This metabolic process occurs mainly in the liver, but also in the blood, 
brain, lung and kidneys. After that, the drug is excreted (renal or biliary; minor: 
exhalation, sweat) and eliminated from the body (27). Figure 1.3 resumes the drug 
route from its administration into the body till its excretion. 
 
 
Figure 1.3. Drug ADME route in the human body. Adapted from (28). 
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First and second generations PSs 
 
The first family of PSs is represented by a purified version of HpD, named 
Photofrin® (Figure 1.4) (29). This was the first PS approved for the treatment of 
early-stage and advanced lung cancers, superficial gastric cancer, esophageal 
adenocarcinoma, cervical cancer and bladder cancer (BC), in 1993, in Canada. This 
PS has an absorption spectrum characteristic of Pors with five peaks (one stronger 
band – Soret band – and four Q bands). However, Photofrin® is not a pure 
compound and shows low specificity for the cancer tissue leading to cytotoxic 
damage in the healthy one like an intense inflammatory and necrotic reaction at the 
treated site (23). Additionally, it has a low maximum wave absorption band (630 
nm), which only allows biological effects at a tissue depth of around 5 mm, after 
irradiation. Moreover, these sensitizers take 2-3 months to clear from the cutaneous 
tissues which requires that during this period of time the patients are required to 
avoid bright light (30). 
 
Figure 1.4. Photofrin® structure. 
 
The second generation PSs include, among others, Por derivatives, chlorins 
and Pcs (e.g. Levulan®, Foscan® and silicon(IV) phthalocyanine (Pc4)). They have 
high ROS production and strong absorption in the required wavelength range (600-
850 nm), which allows phototherapy in deep regions, leading to a better efficacy of 
PDT. Kennedy et al demonstrated the clinical suitability of δ-aminolevulinic acid 
(ALA) (31). Bladder tissue can be photosensitized by instillation of ALA, a prodrug 
that is able to initiate a series of biochemical reactions that result in significant 
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accumulation of protoporphyrin IX (PpIX) or photoactive porphyrins (PAPs) that 
preferentially accumulate in malignant and pre-cancerous tissue rather than in 
benign cells. However, ALA is an hydrophilic compound and cannot therefore 
penetrate all tissue, resulting in some clinical limitations, such as a long swelling 
time and a variable PpIX fluorescence intensity and distribution (32). Chlorins are 
tetrapyrroles with one pyrrole ring reduced. This feature leads to a higher 
wavelength absorption band in the region of 650-690 nm which is desirable for PDT 
(15). Pcs are Por synthetic analogues with excellent photophysical and chemical 
properties, that together with their chemical versatility, make this class of 
compounds promising candidates for PDT applications (30). Some of the first and 
second generation PSs that already are under clinical trial or in clinical use are 
summarized in Table 1.1. 
 
Table 1.1 PSs under clinical trial and in clinical use for malignant diseases. 
PS 
Chemical 
class 
Name Indications 
Date of 
approval 
and country 
HpD Por Photofrin® 
Barrett’s esophagus, 
bladder, lung, cervical, 
prostate and gastric 
cancers 
1993 in 
Canada. Now 
in more than 
125 countries 
Tetra(m-
hydroxyphenyl) 
chlorin, (mTHPC) 
Chlorin Foscan® 
Head, neck, 
esophageal, gastric and 
prostate cancers 
2001 EU 
ALA Por Levulan® 
Actinic keratoses, hair 
removal, acne, non-
melanoma skin, 
esophageal and 
gastrointestinal cancers 
1999 in USA 
and 2000 EU 
Hexyl ALA ester Por Hexvix® 
Diagnosis of bladder 
tumors 
2005 in EU 
Lutetiumtexaphyrin Texaphyrin Lutex® 
Cervical, prostate and 
brain tumors 
Phase II 
clinical trial 
ZnPc Pc CGP55847 
Squamous cell 
carcinoma of upper 
aerodigestive tract 
Phase I-III 
clinical trial 
SiPc Pc Pc4 
Cutaneous/SC lesions 
from diverse solid tumor 
origins and sterilization 
of blood components 
Phase I-III 
clinical trial 
Sulfonated AlPc 
derivatives 
Pc Photosense 
Skin, breast, lung and 
gastrointestinal cancer 
Phase I-III 
clinical trial 
F2BMet Bacteriochlorin Luz11 
Advanced head and 
neck cancer 
Phase IIa 
clinical trial 
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Third generation PSs 
  
The third generation PSs is generated by the coupling of the first or second 
generation PSs with a targeting component that is specifically recognized by the 
cancer cell and allows a selective delivery and uptake (30). Pors and their 
derivatives have been conjugated with many proteins, such as human and bovine 
serum albumin (HSA and BSA, respectively) (33), monoclonal antibodies (mAbs) 
(34) and amino acids (35), among others. Alternatively, carbohydrates, that are able 
to target carbohydrate binding proteins overexpressed in tumoral cells, are also 
being explored as potential targeting components (36). 
In our research group, at the University of Aveiro, several Por 
glycoconjugates have been developed with very promising results for BC treatment 
and for antiviral activity against herpes simplex virus type 1 and 2, after PDT (37-
40). The glycoconjugates have demonstrated promising in vitro results and are 
currently being tested in vivo. Some examples of third generation PSs are 
represented in Table 1.2. 
 
Table 1.2. Third generation PSs and their application. 
PS Biomolecule Cancer Type 
Trastuzumab (34) mAb-IR700 Breast 
Por derivative (33) 
HSA 
BSA 
Bladder 
Por derivative (35) Amino acid Cervical 
Por and Pc derivatives (40) Galacto-dendritic units Bladder 
Chlorin e6 (41) Maltose 
Ovarian 
Burkitt’s Lymphoma 
Chlorin derivative (42) Maltose Gastric Colon 
Por derivative (43) 
Galactose 
Glucose 
Liver 
Chlorin derivative (44) Glucose Gastric Colon 
SiPc (45) Galactose Liver 
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4. Phthalocyanines 
 
Pcs have been widely studied due to their potentiality to be used in medicine 
and supramolecular chemistry (46). In this section their structural and photophysical 
properties, the synthetic strategies and their role as PS agents will be highlighted. 
 
Structure and properties 
 
Pcs are two-dimensional synthetic tetrapyrrolic compounds constituted by 
four isoindole units presenting an 18 π-electron system, which is delocalized over 
an arrangement of alternated carbon and nitrogen atoms. They present a strong 
absorption band in the red region of the spectrum (630 to 750 nm) mainly in the 
near-infrared (IR) region (Figure 1.5) which confers a bright green/blue color that 
have a great interest in using Pcs as dyes in pigments industries (47).  
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Figure 1.5. Typical UV/Visible (UV/Vis) spectrum of metallo Pcs (MPcs). 
 
These compounds are able to form stable metallocomplexes with many metal 
cations (e.g. zinc (Zn), silicon (Si) and ruthenium (Ru)) using the four central pyrrole 
nitrogens of the macrocycle (48). The hydrogen atoms of the central cavity can be 
replaced by more than 70 elements and the coordination number of the square-
planar Pc is four. Thus, according to its size and oxidation state, the metal can be 
inserted into the Pc core. When the metal has a higher coordination number, 
pyramidal, tetrahedral or octahedral structures result with one or two axial ligands 
(46). The internal and external positions of the fused benzene ring are also 
commonly known as α- and β-positions, respectively (Figure 1.6). The chemical 
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versatility of this class of macrocycles allows the tuning of their physicochemical 
properties, making Pcs promising PS agents for PDT in the treatment of cancer (49). 
 
                
Figure 1.6. Structures of MPc- and metal-free-Pcs (H2Pc). 
 
Synthetic routes 
 
The synthesis of Pcs can be carried out either by cyclotetramerization of the 
appropriately substituted precursors, usually phthalonitriles (Scheme 1.1) or 
diiminoisoindolines. Most often, this reaction is conducted in the presence of metal 
ions that act as template during the ring formation. Not only the metal-template 
effect, but also the thermodynamic stabilization and the aromaticity involved on the 
Pc macrocycle formation, are responsible for the ring closure (50).  
 
 
Scheme 1.1. Schematic representation of the synthesis of a MPc using a phthalonitrile as 
precursor in the presence of metal ions (M). 
 
Owing to their extended conjugation, Pcs exhibit a high aggregation 
tendency, by π-π interactions and reduction of solubility, that reduce their ADME 
properties and compromise their photophysical characteristics (i.e. ability to 
generate 1O2 and other related ROS). To overcome such limitations, a wide variety 
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of substituents can be introduced either axially or at the periphery of the macrocycle. 
(47). Due to their promising studies for biological applications, Pcs coordinated 
centrally with a Si atom will be explored in this dissertation. 
 
4.1 Silicon Phthalocyanines 
 
An important feature of silicon phthalocyanines (SiPcs) is their four-
coordinate central atom that allows many structural possibilities and thus a flexibility 
of the synthetic design, such as the functionalization of two axial ligands (51). The 
axial functionalization reduces aggregation, increasing the solubility in a variety of 
solvents, photosensitizing efficiency as well as fine-tune fluorescence and triplet 
state characteristics (52). The first approved SiPc conjugated with axial ligands was 
Pc4 (53-55). This PS showed excellent results both in vitro and in vivo and presently 
are being made the clinical trials for the treatment of cutaneous neoplasms (56). 
Pc4 contains two axial ligands consisting of a hydroxyl and a dimethylamino-
propylsiloxy group (Figure 1.7) and has an absorption band in the therapeutic 
window (670 nm) (57). This PS demonstrated excellent cellular uptake and 
photodynamic efficacy as well as effectiveness in eliminating human 
immunodeficiency virus-infected cells (58). 
 
 
Figure 1.7. Pc4 chemical structure. 
 
Many others axial conjugated SiPcs are being developed and tested in vitro, 
and will be highlighted the ones conjugated with biomolecules, such as proteins 
(59,60), nucleosides (61), carbohydrates (45, 62-64) and mAb (34) (Table 1.3).  
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Table 1.3. SiPcs axially conjugated to biomolecules and their applications. 
Author Biomolecule Year, study level Cancer Type 
Huang J. D. (59) BSA 2003, in vitro Liver 
Jiang X. J. (60) BSA 2006, in vitro Mammary 
Shen X. M. (61) Nucleosides 2013, in vitro Liver 
Lau J. T. F. (62) β-cyclodextrin 2011, in vitro Colorectal 
Lo P. C. (63) 
Acetal-protected 
glucose 
2007, in vitro Colorectal 
Lee P. P. S. (45) 
Lo P. C. (64) 
Acetal-protected 
galactose 
2005, in vitro 
2007, in vitro 
Liver 
Colon 
Mitsunaga M. (34) mAb 2010, in vivo Epidermoid 
 
 
4.2 Phthalocyanines galacto-dendritic conjugates 
 
Pc’s tendency of aggregation due to their low solubility in many solvent 
systems is being a challenge in the development of effective Pc formulations. 
Aggregation of the macrocycle leads to quenching of the 3PS*, decreasing the yield 
of triplet state and hence the efficiency of the compound as a PS (46). In order to 
minimize these problems, the development of new Pcs linked to biochemical motifs 
have been developed. 
Carbohydrates are potential candidates as PS-delivery systems because 
they are biocompatible molecules with a rapid cellular uptake and with a specific 
recognition by lectin proteins (36). Lectins’ hydroxyl groups make the sugars suited 
for directional acceptor/donor hydrogen bonds (65). It is expected that the specific 
(non-covalent) binding of carbohydrates with lectins promotes the accumulation of 
the glycoconjugate inside cells by the endocytic pathway (66). Furthermore, certain 
carbohydrate-binding lectins are overexpressed in tumor cells (67). Therefore, 
galactose molecules have been conjugated with PSs, since they can be recognized 
by galactose-binding proteins overexpressed in cancer cells (namely galectin-1 and 
-3) (68). Galectins are small soluble proteins (molecular weight 14-35 kDa) with 
carbohydrate recognition domains (CRDs) which are responsible for the specific and 
individual binding of each galectin to carbohydrates (69). Particularizing to galectin-
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1, this protein exhibits dual localization, being found in both intracellular (nucleus 
and cytoplasm) and extracellular (cell surface and medium) compartments (70). 
Intracellularly, it is involved in fundamental processes such as pre-mRNA (precursor 
messenger ribonucleic acid) splicing and on the regulation of intracellular signaling 
pathways (e.g. mitosis, apoptosis and cell-cycle progression) after binding 
intracellular ligands. Extracellularly, it can bind to cell-surface glycoconjugates that 
contain suitable galactose-containing oligosaccharides (71). Therefore, the coupling 
of a Pc with galactose moieties can provide a distinct advantage for the efficacious 
targeting of the PS to cancer cells due to the presence of galactose-binding proteins 
that are overexpressed in those cells, and that can facilitate the PS cellular uptake 
(Figure 1.8). 
 
Figure 1.8. Possible interaction of a SiPc conjugated with two galactose molecules with 
galactose binding proteins overexpressed in cancer cells. 
 
 
Many PSs conjugated with carbohydrates showed promising in vitro results 
and are currently being tested in vivo. Maillard reported the synthesis of a 
glycoconjugated chlorin (42). Fujimoto has conjugated a Por with galactose and its 
molecular delivery to hepatocytes (43). Silva reported the synthesis of a Pc 
containing eight dendritic units of galactose (72) which is able to target and kill BC 
cells through mediated interaction with galactose-binding proteins overexpressed in 
those cells (40). Particularizing to SiPcs, there are only few reports of their axial 
conjugation to carbohydrates. Ng and co-workers reported the conjugation of 
unsymmetrical SiPcs with a β-cyclodextrin (62), of two SiPcs with acetal-protected 
glucose molecules (63) and also a SiPc with one or two axial acetal-protected 
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galactose substituent(s) (Table 1.3) (45). The in vitro and in vivo results showed a 
high photodynamic activity of these compounds against HepG2 human 
hepatocellular carcinoma, which can be attributed to the high cellular uptake and 
efficiency to generate 1O2, as well as tumor growth retardation. These compounds 
are therefore promising PSs for PDT. However, there are no reports related with the 
synthesis and validation of SiPcs conjugation with deprotected sugar substituents. 
Recently, the emerging role of dendrimers in biological systems has 
highlighted their potential benefits for the preparation of new anticancer drugs. 
Dendrimers are highly branched nanostructures with many arms emanating from a 
central core (73). Besides improving the biocompatibility and the photochemical 
proprieties of PSs, they also create multivalent interactions with more than one 
receptor binding site, contributing to an active cancer cell targeting, improving 
cellular recognition (Figure 1.9). Additionally, they act as nanocarriers, leading to 
the enhanced permeability and retention (EPR) effect that is characteristic of tumor 
tissues (37). Several PSs (Por and Pc) conjugated with galacto-dendritic units have 
been synthesized and tested in vitro in BC cells with very promising results (40,72). 
However, there are no reports of the axial conjugation of Pcs with galacto-dendritic 
units. 
 
Figure 1.9. Illustration of the interaction of a Pc conjugated with eight galacto-dendritic units 
to a lectin overexpressed in tumoral cells. Adapted from (40). 
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5. Photodynamic therapy in clinical applications 
 
PDT has been mostly restricted to the treatment of melanomas and solid 
tumors occurring in externally accessible cavities, like the bladder and the 
esophagus (3). PS can be administrated intravenously or topically and then it should 
be preferentially accumulated in the desired tissue (Figure 1.10). After a 
predetermined time, known as the drug-to-light interval, light is directly applied into 
the tumor by the use of modern fiber-optic systems and various types of endoscopy, 
which allows an accurately light targeting to almost any part of the body (74). The 
period of time between PS administration and the start of illumination varies 
between 5 min to 24 h, or more. The most efficient light systems are lasers and light 
emitting diodes (LEDs) sources with relatively narrow spectral bandwidths and high 
fluence rates. Lasers can also be coupled into fibers with diffusing tips to treat 
tumors in the urinary bladder and the digestive tract (3). 
1O2 generated by the activated PS is believed to be responsible for tumor 
destruction (75). Once 1O2 has a very short lifetime, it is deactivated before it can 
escape from the cell in which it was produced. Photobleaching can be an advantage 
avoiding an overall skin photosensitivity which is one of the main side effects in 
patients treated with PDT. Total healing of the area after PDT may take from 2 to 6 
weeks. During this time, the patient will be light sensitive (due to PS accumulation 
in the skin) and must be protected from direct light (3). 
 
 
Figure 1.10. PDT protocol in oncology. Adapted from (76). 
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In order to improve the therapeutic index of treatments in modern oncology, 
many therapeutic modalities with non-overlapping toxicities can be combined. There 
are two general approaches that may increase the antitumor effectiveness of PDT, 
mostly in elderly or debilitated patients who less tolerate more intensive therapeutic 
regimes, such as: i) sensitization of tumor cells to PDT (77) and ii) interference with 
cytoprotective molecular responses triggered by PDT in surviving tumor or stromal 
cells. Therefore, any interactions between PDT and PSs will be confined to the 
irradiated area (3). Despite all its applications, PDT has the limitation that cannot 
cure advanced disseminated diseases because it requires irradiation of the whole 
body with appropriate doses and that is not possible with the present technologies. 
However, for advanced diseases, PDT can improve quality of life and lengthen 
survival of the patients (74). For early or localized diseases, this technique can be 
a selective and curative therapy with many potential advantages over available 
alternatives. 
 
5.1 Bladder Cancer 
 
BC is a disease that affects many patients worldwide. It has a high rate of 
mortality and recurrence (78). Nowadays, many advances have been attempted to 
understand the nature of this disease and to develop new treatment approaches 
(79). In this section, the focus is on BC physiopathology, incidence and treatment. 
 
Physiopathology 
 
Bladder is a hollow, balloon shaped organ in the pelvic floor containing three 
histological layers: 1) urothelium, 2) lamina propria (suburothelial loose connective 
tissue) and 3) detrusor or muscularis propria. After muscularis propria there is a 
perivesical fat that covers the superior surface and the upper part separating the 
bladder from the nearby organs (Figure 1.11) (80,81). Urothelium is a highly 
specialized transitional epithelium layer that creates an interface between 
pathogens and other bladder tissues through many defense mechanisms. Its cell 
Introduction 
 
21 
 
turnover is very slow, but capable of a very rapid proliferation in response to injury 
(82).  
BC progression is based on four stages that depend on the location of the 
tumor in the bladder layers. The tumor grows from the inside of the bladder wall 
(stage 0) and can spread into the lamina propria layer (stage I), then into the 
muscular layer (stage II), penetrate the perivesical tissues (stage III) and finally 
invade other organs (stage IV): prostate, uterus, vagina, abdominal wall and pelvic 
wall (Figure 1.11). Stages 0 and I are superficial or non muscle-invasive while 
stages II, III and IV are muscle-invasive cancers. When the cancer extends from its 
original place (in the bladder) to another part of the body (stage IV) it is named 
metastatic BC (79). The classification of BC staging comes from the Tumor-Node-
Metastases (TNM) system which is based on the size and penetration of the tumor 
on the tissues of the bladder (Table 1.4) (81). 
 
 
Figure 1.11. Bladder layers and BC progression. Adapted from (83). 
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Table 1.4. Staging of primary BC tumors (TNM classification) (81). 
Primary tumor (T) 
T0 No evidence of primary tumor 
Ta Noninvasive papillary carcinoma 
Tis Carcinoma in situ (CIS): "flat tumor" 
T1 Tumor invades lamina própria 
T2 Tumor invades muscularis propria 
T2a Tumor invades superficial muscularis propria (inner half) 
T2b Tumor invades superficial muscularis propria (outer half) 
T3 Tumor invades perivesical fat 
T3a Tumor invades perivesical fat microscopically 
T3b Tumor invades perivesical fat macroscopically 
T4 Tumor invades prostate, uterus, vagina, pelvic wall and abdominal wall 
T4a Tumor invades prostate, uterus and vagina 
T4b Tumor invades pelvic wall and abdominal wall 
 
 
The staging process is a major factor in treatment choice. BC is a pathology 
that frequently does not have symptoms associated. However, when it does, the 
most common ones are painless hematuria, that can be detected by a chemical 
reagent strip for hemoglobin and spun sediment microscopy on voided urine, and 
irritative symptoms such as frequency, urgency and pain. Normally, screening is 
performed by combining different modalities: the surgical procedure transurethral 
resection (TUR), bimanual palpation before and after TUR, fluorescence 
cystoscopy, radiological imaging techniques and histopathological examination 
(79). 
The non muscle-invasive BC (Ta (70%) and T1 (20%), Table 1.4) is the most 
frequently diagnosed. Its progression to muscle-invasive BC and rate of recurrence 
depends on the tumor grade, stage and size, the presence of CIS (Table 1.4), the 
occurrence of multifocal lesions and the prior recurrence. Ta tumors rarely become 
muscle-invasive, but high grade T1 tumors and flat CIS lesions (Table 1.4) have an 
increased propensity to progress. Although CIS belongs to the non muscle-invasive 
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(10%) BC group, it is associated to a higher aggressiveness due to molecular 
alterations that are characteristic of muscle-invasive BC (84). 
 
Statistics 
 
BC is the 9th most common cancer worldwide. The age standardized rate 
(ASR) is 10.1 per 100,000 for males and 2.5 per 100,000 for females. More than 12 
million of new cancer cases occur annually worldwide, of those 5.4 million occur in 
developed countries and 6.7 million in developing countries (78). In Europe, 
mortality rates increased in Southern and Eastern Europe between the mid-1950s 
and late 1980s, but a decline has been observed in several Northern European 
countries over the last two decades (79). 
 
 
 
 
 
 
 
Figure 1.12. Most frequent cancers in Europe (2012). The values correspond to estimated 
incidence (left) and mortality (right) in both males and females (85). 
 
 
Predisposition factors include smoking, exposure to aromatic amines and 
inorganic chemicals in the workplace, chronic cystitis associated with foreign bodies, 
pelvic radiation therapy, exposure to the chemotherapeutic prodrug 
cyclophosphamide (79) and parasitic infections (86) in the Middle East and parts of 
Africa where schistosomiasis is a widespread problem. Most bladder carcinogens 
exert their action by direct contact with the bladder epithelium. Inhaled or ingested 
compounds that are either directly carcinogenic or that can be transformed by the 
body in carcinogenic byproducts, reach the urinary bladder because they are 
excreted via the urine. Patients that had BC histories for recurrence need to be 
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screened annually by cytological examination of exfoliated cells in both voided urine 
and saline bladder lavage specimens (79). 
 
Treatment 
 
BC treatment depends on the grade, stage and whether the lesion is flat or 
papillary (87). The most applied surgical procedure is TUR that can be used to 
diagnose, stage, and treat the majority of primary and recurrent bladder tumors. This 
treatment has three main goals: i) to provide pathologic material to determine the 
histologic type and grade of bladder tumor; ii) to determine the presence, depth and 
type of tumor invasion; and iii) to remove all visible and microscopic superficial and 
invasive tumor(s) (88). If there are multiple recurrences, the patient is given a topical 
immunotherapy that consists in intravesical instillations of Bacillus Calmette-Guerin 
(BCG). This therapy is only applied in non muscle-invasive BC with no side effects 
and is an easy deliver in bladder due to its great accessibility (89). However, this 
treatment fails in 30-40% of patients, and 30-40% of those had an initial response 
that relapsed due to intolerance, recurrence and resistance of patients to BCG (90). 
In more advanced stages of the tumor, radiotherapy, radical cystectomy and 
chemotherapy are the therapeutics of choice (91,92). Though, these conventional 
therapies might cause unwanted side effects and in some cases they are not 
completely effective in the destruction of the tumor, leading to a high risk of 
recurrence and progression. Thus, in order to preserve the bladder and its function, 
there is a clinical interest on using alternative treatments. 
The clinical urological interest in PDT is focused on the preservation of the 
organ and its function because there are no significant changes in tissue 
temperature, and the preservation of connective tissue leads to minimal fibrosis. 
Current scientific research on PDT for BC treatment is based on the development 
of tumor selective drugs (33, 40, 93). BCs are suitable targets for PDT because their 
interior can be assessed by endoscopy. The bladder geometry should allow an 
improved and homogeneous light delivery and the bladder tissue is relatively more 
translucent when compared to other human tissues (3). The first PS used to treat 
recurrent BC was HpD, in 1975 (94). After this, in 1993, Photofrin® was approved in 
Introduction 
 
25 
 
Canada. However, both PSs could only be used for superficial BC, once for whole-
bladder PDT, there was a high incidence of side effects, such as urinary frequency, 
pain and persistent reduction in bladder capacity (23, 95, 96). These complications 
were due to the excessive light doses and the non-uniform light delivery in the early 
studies. Nseyo et al showed that, for standardized protocols, reducing the drug and 
light dose and decreasing the light penetration in tissues to wavelengths of 514 nm 
(green light), also gives a good tumor response rate for superficial lesions without 
transmural bladder wall injury or treatment-related morbidity (97). This became an 
excellent treatment option of CIS, although it was not been fully evaluated. Another 
PS that has been used for recurrent superficial bladder cancer is Levulan® by given 
a single PDT treatment or in combination with mitomycin C, which resulted in a 
complete response rates at 18-24 months without persistent reduction in bladder 
capacity (98-101). Finally, as mentioned before, various therapeutic modalities with 
non-overlapping toxicities could also be combined. Pan et al (102) hypothesized that 
PDT combined with intravesical BCG would form an auto-vaccine for BC. Tumor 
cells treated in vitro by PDT can be used to generate potent cancer vaccines. 
Hypothetically, tumor cells destroyed by PDT could be treated with BCG to elicit and 
amplify the immunological response, which would lead to the formation of an in-situ 
auto-vaccine against urothelial tumor cells, whether local or systemic.  
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6. Objectives and working plan 
 
The necessity of finding new approaches for cancer treatment in order to 
preserve the quality of life of the patient by reducing side effects has been 
captivating the attention of many research groups. Being PDT a less invasive 
therapy that selectively attack the cancer cells, the goal is to find ideal PSs suitable 
for many types of cancers. BC is a good target for PDT due to its geometry that 
allows an endoscopy access.  
An ideal PS is not always easy to find because it should be endowed with 
specific features as described above (page 7). The development of Pcs for PDT has 
been especially promising due to their unique photochemical properties. However, 
Pcs have reduced water solubility and low specificity to the cancer tissue. Therefore, 
the aims of this Master’s dissertation were to synthesize water soluble SiPcs 
conjugated with galacto-dendritic units that will increase the specificity to tumoral 
cells, to study their photophysical and photochemical properties, and to validate 
them as photodynamic therapeutic agent against BC cells.  
 
Working Plan 
 
- Synthesis of novel water soluble galacto-conjugated SiPcs; 
- Study of their photophysical and photochemical properties: 
o Solubility in DMSO, DMF (Dimethylformamide) and PBS (Phosphate 
buffered saline); 
o Fluorescence emission spectrum in DMF; 
o Photostability when irradiated with red light; 
o Generation of 1O2 using DPBF as 1O2 scavenger; 
- Validate their photodynamic potential against a human bladder cancer cell 
line, UM-UC-3, with high levels of galectin-1: 
o Determine the uptake of the galacto-conjugates by BC; 
o Quantify the levels of ROS after PSs-PDT; 
o Determine the toxicity in darkness (MTT assay); 
o Determine the phototoxicity after light activation (MTT assay); 
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The elaboration of this master thesis took place in three different institutions 
under the supervision of Dr João Tomé (University of Aveiro, UA), Dr Tomás Torres 
Cebada (University Autonoma of Madrid, UAM) and Dr Rosa Fernandes (Institute 
for Biomedical Imaging and Life Sciences, IBILI, from Medical Faculty of Coimbra). 
At UAM and UA was performed the synthesis of the PSs, at UA the photophysical 
and photochemical studies and at IBILI the photobiological studies. 
 
 
 
 
 
 
 
 
 
Scheme 1.2 Chronology and institutions involved in the studies of this thesis. 
March 2015 
Synthesis 
Photophysical and 
photochemical studies Photobiological studies 
September 2014 July 2015 
UA/UAM IBILI 
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1. Novel galacto-conjugated silicon phthalocyanines: synthesis 
and characterization 
 
1.1 Overview 
 
Nowadays, PDT research is focused on the development of new PSs with 
improved photophysical and photobiological properties (3). Pcs derivatives have 
high absorption in the visible region of the spectrum (around 650 nm), allowing much 
deeper tissue penetration for therapy. These PSs present a long lifetime of the triplet 
excited state which will induce high production of 1O2 (49). Based on these 
properties, Pcs have emerged as a promising class of PSs (103). However, the 
major problem is their insolubility in physiological fluids due to their hydrophobic 
skeletons, which leads to Pcs aggregation, affecting their photophysical properties. 
Additionally, the Pcs’ core has not specificity for cancer cells. To overcome that, a 
wide variety of substituents can be introduced either axially or at the periphery of 
the macrocycle (40, 45, 93). Knowing that cancer cells have increased levels of 
galactose-binding proteins, the combination of carbohydrate moieties with 
macrocycles improves PS uptake and PDT efficacy. Furthermore, these 
carbohydrate units can also provide water-solubility to the macrocycles (16). 
The aim of this section is to describe the synthetic steps attempted to obtain 
SiPcs conjugated axially with galacto-dendritic units (Figure 2.1). The structure of 
the compounds was corroborated using spectroscopic and spectrometric 
techniques (nuclear magnetic resonance NMR, matrix-assisted laser 
desorption/ionization MALDI-MS and electrospray ionization mass spectrometry, 
ESI+-MS). These studies were performed at University Autonoma of Madrid and 
University of Aveiro. 
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Figure 2.1 SiPcs axially conjugated with two galacto-dendritic units. 
 
 
1.2 Synthesis of galacto-dendritic units 
 
Herein we report the synthesis of two galacto-dendritic units, differing only in 
the linker chain, and their further axial coordination with the SiPc macrocycle 
(Scheme 2.1). 1,2:3,4-di-O-isopropylidene-α-D-galactopyranose was chosen as the 
carbohydrate moiety, in order to relate these new compounds with our previous 
studies, which have already shown the importance of this carbohydrate unit in the 
photophysical, photochemical and photobiological results (15, 40, 72, 104). The 
selected dendritic framework was 2,4,6-trichloro-1,3,5-triazine (TCT) because of its 
well-known selective reactivity concerning the substitution of each chlorine atoms at 
different temperatures. The synthesis of dendritic units 2 and 3 was performed in 
two steps as depicted in Scheme 2.1. Although dendritic unit 3 is less nucleophilic 
than dendritic unit 2, it was expected that the electronegativity of the oxygen atom 
would allow the formation of a more stable bond with the silicon atom of the SiPc 
core than the one formed with the sulfur atom (105). 
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Scheme 2.1. Synthetic route for the preparation of galacto-dendritic unit 2 and 3. i) DIPEA, 
toluene, Ar, 60 ºC, 66%; ii) DIPEA, toluene, Ar, 70 ºC, 75%; iiia) NaH, toluene, Ar, 70 ºC, 
89%; iiib) DIPEA, toluene, 80 ºC, 61%. 
 
 
Compounds 2-chloro-4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-galactopyran-
6-yl)-1,3,5-triazine [1] and 3-[(4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-
galactopyran-6-yl)-1,3,5-triazin-2-yl)thio]propane-1-thiol [2], were prepared 
according to a literature procedure, as shown in Scheme 2.1 (72). The nucleophilic 
substitution of the TCT by the galactose moieties was carried out in dry toluene, in 
the presence of an excess of N,N-diisopropylethylamine (DIPEA) and stirred during 
48 h, under argon (Ar). The desired compound was purified by column 
chromatography on silica gel using a mixture of hexane (Hex) and ethyl acetate 
(AcOEt) (8:2 to 7:3 v/v) as eluent with a 66% of yield (lower than the one reported 
in the literature) (72). The carbohydrate units are linked to the TCT by the hydroxyl 
group located in carbon C-6. The following step to produce compound 2, was based 
on the addition of 1,3-dimercaptopropane to compound 1 in a reaction mixture with 
the same conditions as the ones to achieve compound 1, providing compound 2, 
with an yield of 75% (lower than the one reported in the literature) (72). 
To obtain the new compound 3, 1,3-dipropanediol was added to compound 
1, in a reaction mixture by using the same conditions employed for the synthesis of 
compound 2, but using sodium hydride (NaH) instead of DIPEA. The NMR and ESI+ 
MS studies demonstrated that the desired compound was not obtained because 
NaH hydrolyzed the galactose moieties of compound 1. Therefore, NaH was 
substituted by DIPEA, and compound 3 was obtained with 61% yield.  
Results and Discussion 
 
35 
 
The 1H NMR spectrum of compound 1 showed four singlets between  1.31-
1.49 ppm attributed to the isopropylidene methyl groups. The proton 5'-H appeared 
as a triple doublet at  4.18 ppm (J = 1.4, 6.4 and 6.5 Hz). The signals of protons 4'-
H and 2'-H emerged as multiplets at  4.31 ppm, while the protons 6'-H came out at 
 4.53 ppm. The signal of the proton 3’-H appeared as a double doublet at  4.62 
ppm (J = 2.4 and 7.9 Hz). Finally, the doublet at  5.52 ppm (J = 5.0 Hz) was 
attributed to the resonance of the 1'-H.  
Regarding compound 2, the 1H NMR spectrum also showed four singlets 
between  1.32-1.49 ppm attributed to the resonances of the isopropylidene methyl 
groups. Then the 1,3-dimercaptopropane methylene and thiol groups appeared as 
multiplet signals: Hb (CH2CH2CH2SH)  2.02, Hc (CH2CH2CH2SH) 2.64, 2.75-2.80 
(SH) and Ha (CH2CH2CH2SH) 3.23 ppm. The remaining signals of the galactoses’ 
protons were the same as the ones corresponding to compound 1. 
Finally, compound 3 had a 1H NMR spectrum, shown in Figure 2.2, similar 
of compounds 1 and 2, having also two multiplets and a double doublet 
corresponding now to the 1,3-propanediol methylene groups: Hb (CH2CH2CH2OH) 
 1.99, Hc (CH2CH2CH2OH) 3.76 and Ha (CH2CH2CH2OH) 4.54 ppm (J = 6.3 Hz), 
respectively. These last three signals were not observed in the 1H NMR spectrum 
of the final product prepared when using NaH as a base (route iiia), Scheme 2.1), 
which was the proof that we did not obtained the desired compound. The structure 
of the galacto-dendritic unit 3 was confirmed by mass spectrometry.  
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Figure 2.2. 1H NMR spectrum of galacto-dendritic unit 3 in CDCl3 solvent. Inset: expansions 
of the 1H NMR spectrum. 
 
  
1.3 Synthesis of galacto-conjugated silicon phthalocyanines 
 
1.3.1 Synthesis of a symmetrical silicon phthalocyanine axial conjugated 
with galactose moieties [4] 
 
The synthetic route to achieve SiPc 4 (SiPcGal2, i.e. a SiPc containing two 
monomers of acetal-protected galactose) depicted in Scheme 2.2, it is already 
described in literature (45) and was prepared for comparative purposes with the 
SiPc conjugated axially with the aforementioned galacto-dendritic units 2 and 3. The 
commercially available silicon(IV) phthalocyanine dichloride (SiPcCl2) was treated 
with 1,2:3,4-di-O-isopropylidene-α-D-galactopyranose in the presence of NaH, in 
toluene reflux, under argon (Ar), during 48 h, giving the di-substituted SiPc 4 in 53% 
yield (higher than the one reported in the literature) (45). This compound was highly 
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soluble in a wide range of organic solvents and could be purified readily by column 
chromatography on silica gel. Then, once the aim of this newly PSs was to be 
recognized by the galactose-binding proteins overexpressed in cancer cells, it was 
necessary to hydrolyze the isopropylidene groups of the galactose molecules. The 
hydrolysis attempts were performed by employing two different approaches: i) by 
using TFA/H2O (9:1) as solvent, at room temperature (rt), during 5 h (72); and ii) 
with bromotrimethylsilane (TMSBr), using dichloromethane (DCM) as solvent, at rt, 
during 24 h (106). However, both hydrolysis resulted in the loss of the galactose 
molecules, thus producing SiPc dihydroxide (SiPc(OH)2). 
 
 
Scheme 2.2. Synthetic route for the preparation of SiPcs 4 and SiPc(OH)2 i) NaH, toluene 
reflux, Ar, 53%; iia) TFA/H2O (9:1), rt; iib) TMSBr, DCM, rt. 
 
 
The 1H NMR spectrum of SiPc 4 was well-defined. Upfield there were two 
double doublets that corresponded to the 6’-H protons:  -2.37 (J = 8.8 and 9.3 Hz) 
and -1.70 (J = 5.3 and 8.3 Hz) ppm. The protons of the isopropylidene methyl groups 
appeared as singlets between  0.30 and 0.79 ppm. In the middle of this range, it 
was also possible to observe protons 5’-H at  0.68 ppm, which emerged together, 
in a virtual singlet, with one of the isopropylidene methyl groups. Proton 4’-H was 
localized at  0.76 ppm as a double doublet (J = 0.8 and 9.2 Hz). Then, there were 
two double doublets, 3’-H and 2’-H, at  3.22 (J = 0.4 and 8.5 Hz) and 3.32 (J = 1.6 
and 5.4 Hz) ppm, respectively, and a doublet corresponding to 1’-H at  4.37 ppm 
(J = 5.0 Hz). Finally, downfield there were two multiplets corresponding to the SiPc 
macrocycle: Pc-Hα protons appeared between  8.28 and 8.31 ppm and then the 
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Pc-Hβ since  9.59 to 9.62 ppm. Through mass spectroscopy the structure of the 
SiPc 4 was confirmed. 
 
1.3.2 Synthesis of a symmetrical silicon phthalocyanine axially conjugated 
with compound 2 [5] 
 
In order to obtain SiPc 5, SiPcCl2 was treated with compound 2 in DMF and 
the reaction was refluxed under Ar, during 24 h (Scheme 2.3). This condition was 
optimized according to a procedure described in the literature (107). Yet, the desired 
compound was not obtained, indeed the 1,2:3,4-di-O-isopropylidene-a-D-
galactopyranose signals were not observed in the corresponding 1H NMR spectrum. 
 
 
Scheme 2.3. Synthetic route for the preparation of SiPc 5. i) DMF, Ar, reflux. 
 
1.3.3 Synthesis of a symmetrical silicon phthalocyanine axially conjugated 
with compound 3 [6] 
 
The SiPc 6 was prepared by a reaction between the SiPcCl2 and five 
equivalents of 3 in the presence of pyridine as base and in toluene. The reaction 
was allowed to reflux for 72 h, giving the di-substituted SiPc 6 in 61% yield. This 
conditions were optimized according to the work of Ng et al, who described the axial 
coordination of a SiPc with 3- or 4-hydroxypyridine (108). SiPc 6 was highly soluble 
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in a wide range of organic solvents and could be easily purified by column 
chromatography on silica gel. Then, as last step, the hydrolysis of the isopropylidene 
protective groups was performed by using the same methodology employed for the 
preparation of SiPc 4 (Scheme 2.4), but unfortunately, once again, we obtained the 
dihydroxy derivative SiPc(OH)2. 
 
 
Scheme 2.4. Synthetic route for the preparation of SiPcs 6 and SiPc(OH)2. i) Pyridine, 
toluene reflux, Ar, 12%; iia) TFA/H2O (9:1), rt; iib) TMSBr, DCM, rt. 
 
 
The 1H NMR spectrum of SiPc 6 was well-defined (Figure 2.3). Upfield there 
were two triplets (Hc and Ha) and one multiplet (Hb) that emerged at:  -1.99 (J = 6.5 
Hz) and 0.00 (J = 3.9 Hz) for the triplets and -1.06 ppm for the multiplet. The 
resonances of the isopropylidene methyl groups appeared as singlets between  
1.38 and 1.55 ppm. Protons 5'-H exhibited a triple doublet at  4.22 ppm (J = 1.0, 
4.0 and 4.0 Hz), protons 4’-H, 2’-H and 6’-H emerged as multiplets at  4.32, 4.39 
and 4.42 ppm, 3-H’ protons resonance came out as a double doublet at  4.69 ppm 
(J = 4.7 and 1.4 Hz) and the doublet at  5.64 ppm (J= 2.9 Hz) corresponded to 1'-
H. Downfield there were two multiplets corresponding to the Pc-protons: first the Pc-
Hα protons between  8.29 and 8.31 ppm and then the Pc-Hβ since  9.55 to 9.57 
ppm. Through mass spectroscopy the structure of the SiPc 6 was confirmed.  
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Figure 2.3. 1H NMR spectrum of SiPc 6 in CDCl3 solvent. 
 
 
Regarding all these reactions and final products obtained, the studies 
performed in this thesis (photochemical, photophysical and photobiological studies) 
were carried out using SiPcs 4 and 6, which were named as SiPcGal2 and 
SiPcGal4, respectively. Even though some photophysical, photochemical and in 
vitro studies of SiPcGal2 are already published (45, 109), we have also used this 
SiPc in our studies for comparative purposes between the axial conjugation with 
protected-galacto-dendritic units (SiPcGal4) and with protected-galactose 
molecules (SiPcGal2). Studies with the commercially available SiPc(OH)2 were also 
performed in order to evaluate the Pc-core properties. SiPc(OH)2 was obtained by 
reacting SiPcCl2 with sodium hydroxide (NaOH) in methanol (MeOH) at rt, during 
30 min. 
There are no reports of the removal of the isopropylidene groups from sugar 
moieties axially conjugated to SiPc. Thus, in those kind of compounds described in 
literature the researchers use a Cremophor EL emulsion for the in vitro assays that 
stabilize the solutions of nonpolar materials in aqueous systems, preventing their 
aggregation (45, 62, 63). Although this has not been applied to SiPcs, another 
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alternative to improve the hydrophilicity of a PS (e.g. ZnPc) is by its incorporation 
into liposomes (110). Additionally, studies with SiPc(OH)2 were performed on HeLa 
cells by incorporation of the PS inside the silica shell, in order to improve its 
dispersibility in aqueous environments (111). These are alternative strategies that 
could have been applied to the obtained compounds in the photobiological studies 
performed in this thesis. 
It has to be taken into account that the idea of synthesizing a PS with affinity 
to the galactose-binding proteins overexpressed in cancer cells was unfortunately 
not accomplished because it was not possible to deprotect the galactose moieties 
of SiPcGal4 and SiPcGal2 thus preventing the interaction of the PS with those 
proteins. Therefore, the studies that will be further presented on this Master’s thesis 
will be mostly to evaluate the promising properties of the SiPc core as well as the 
influence that axial substituents have in the Pc hydrophilicity.  
Other routes can be performed to obtain the deprotected compounds, such 
as to deprotect first the galacto-dendritic units or the galactose molecules (112) and 
then axially conjugate them to the SiPc core. There are no papers that use that 
technique on SiPc, but it was reported the synthesis of a Por-glicopolymer based on 
a one-pot conjugation (combination of multi-reactions) (113) and also a gluco-
conjugated ZnPc via Click reaction (generation of substances quickly and reliably 
by joining small units together) (114). 
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2. Photophysical and photochemical studies of galacto-
conjugates 
 
In this section, photophysical and photochemical properties of SiPcGal4 and 
SiPcGal2 were determined and compared with those for SiPc(OH)2. UV-Visible 
(UV/Vis) characterization, PSs solubility in organic and aqueous solvents, 
fluorescence properties and ability to generate 1O2 were evaluated. These studies 
were performed at the University of Aveiro. 
 
2.1  UV-Visible characterization, water solubility and fluorescence 
emission  
 
The electronic absorption spectra of SiPcGal4, SiPcGal2 and SiPc(OH)2 
were initially acquired in the organic solvents DMF and dimethyl sulfoxide (DMSO). 
All the SiPcs at 10 µM gave typical UV/Vis spectra for non-aggregated SiPcs 
showing an intense and sharp Q band in the red visible region. That Q band was 
observed at 677, 669 and 667 nm for SiPcGal4, SiPcGal2 and SiPc(OH)2, 
respectively, and the Soret bands around 348 nm (Figure 2.4). To determine the 
solubility of these compounds in an aqueous buffered solution, their absorption 
spectra were also acquired in PBS (Figure 2.4). This study is a critical parameter 
for the PSs’ PDT application, since in polar solvents, macrocycles have high 
aggregation tendency, disfavoring their efficacy as PDT agents (47). In PBS (3 % 
DMSO), the Q band of SiPcGal4 and SiPcGal2 undergo a significant broadening, 
which is a spectral feature of aggregated SiPcs. This feature was more evident for 
SiPc(OH)2 showing a higher aggregation of this compound. Therefore, these results 
demonstrated that the axial coordination increases the solubility of a SiPc in an 
aqueous solution, but to achieve strong hydrophilicity, the isopropylidene groups 
should be removed.  
The extinction coefficients (ɛ) of the SiPcs in these three solvents are 
summarized in Table 2.1. The ɛ values of SiPcGal2 and SiPc(OH)2 in DMF and 
DMSO, respectively, are already described in literature (45,115), and are similar 
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with the ones described in this section. Comparing to others SiPcs axially 
conjugated with other protected sugars (e.g. glucose and cyclodextrin), the ɛ values 
in DMF were lower for SiPcGal4 and SiPcGal2 (62,63). 
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Figure 2.4. UV/Vis absorption spectra of SiPcGal4 (A), SiPcGal2 (B) and SiPc(OH)2 (C) at 
10 μM in PBS (3 % DMSO, blue), DMF (green) and DMSO (red).  
 
 
Once the biological studies were going to be performed in PBS, even knowing 
that the three SiPcs aggregated in this solvent, their maximum concentration to be 
used on cells was determined. UV/Vis studies with increasing concentrations of the 
compounds (0 to 10 µM) in PBS solution containing DMSO (up to 3%) showed that 
SiPcGal4 and SiPcGal2 strictly follow the Beer-Lambert law at the studied 
concentrations suggesting their application in in vitro studies at concentrations 
below 10 µM (Figure 2.5). The same did not happened with SiPc(OH)2, because 
the absorbance at that concentration was very low and higher concentrations 
implied a percentage of DMSO higher than 3% (corresponding to 10 µM), which is 
not suitable for cellular assays. Previous assays performed by our group have 
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described that a percentage of DMSO higher than 0.5% significantly reduces the 
viability of human bladder cancer cells (UM-UC-3) (40,76), the same cells that we 
intended to use on the present study. Thus, even at a concentration of 10 µM, the 
percentage of DMSO was too high to be used. Therefore, only concentrations bellow 
1.66 µM of SiPcGal4 and SiPcGal2 in PBS (% DMSO ≤ 0.5) could be used for the 
in vitro PDT assays without compromising their phototoxic effectiveness evaluation. 
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Figure 2.5. UV-Vis absorption spectra of SiPcGal4 and SiPcGal2 in PBS (A and B, 
respectively) at different concentrations (0 to 10 µM, % DMSO ≤ 3%). The inset plots of 
SiPcGal4 Q-band at 686 nm and SiPcGal2 Q-band at 698 nm versus concentration of the 
respective galacto-conjugate in PBS. 
 
 
Additionally, the solubility of the SiPcs in DMF was also evaluated for the 1O2 
generation and fluorescence studies that were performed in this organic solvent. 
These studies were carried out with increasing concentrations of the compounds 
(up to 10 µM) in DMF solutions showing that SiPcGal4 and SiPcGal2 strictly followed 
the Beer-Lambert law only till 5 µM and 1.25 µM, respectively (Figure 2.6). 
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Figure 2.6. UV-Vis spectra of SiPcGal4 and SiPcGal2 in DMF at different concentrations (0 
to 5 µM). The inset plots of SiPcGal4 Q-band at 675 nm and SiPcGal2 Q-band at 674 nm 
versus concentration of the respective galacto-conjugate in DMF. 
 
 
The fluorescence emission of the PS provides information about its potential 
application in cancer diagnosis and therapeutics. The steady-state fluorescence 
emission spectra of SiPcGal4, SiPcGal2 and SiPc(OH)2 were acquired in DMF. The 
three SiPcs demonstrated fluorescence emission bands in the red region of the 
spectrum (approximately between 680 and 750 nm, Figure 2.7) which can be used 
to determine the concentration of these PSs inside the cells or tissues.  
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Figure 2.7 Normalized emission spectra of SiPcGal4, SiPcGal2, and SiPc(OH)2. 
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Table 2.1. UV-Vis data of the galacto-conjugates in PBS, DMSO and DMF and of 
SiPc(OH)2 in DMSO and DMF. 
 
Galacto-conjugate Solvent λabsorption bands [nm] (log ε)a λemission [nm] 
SiPcGal4 
PBS 343 (4.31), 613 (4.00), 690 (4.50)  
DMSO 348 (4.00), 608 (3.95), 646 (3.84), 685 (4.26)  
DMF 369 (2.65), 607 (2.88), 646 (2.71), 679 (4.21) 682, 751 
SiPcGal2 
PBS 340 (4.74), 627 (4.71), 698 (4.80)  
DMSO 326 (4.10), 607 (4.39), 647 (4.27) 683 (3.99)  
DMF 364 (3.25), 606 (3.94), 645 (3.92), 683 (4.29) 679, 750 
SiPc(OH)2 
DMSO 354 (5.52), 605 (5.50), 672 (4.58)  
DMF 354 (2.71), 602 (2.62), 669 (3.85) 677, 746 
alog ε M-1.cm-1 
 
 
2.2 Singlet oxygen production 
 
To evaluate the potential use of SiPcGal4 as a new PS for PDT, its ability to 
generate 1O2 was evaluated in DMF. DPBF was used as 1O2 scavenger (63). DPBF 
is a yellow colored compound with a maximum of absorption at 415 nm, that reacts 
with 1O2 and it is oxidized to a colorless compound, the dibenzoylbenzene: thanks 
to this structural change, is possible to measure the scavenger absorption decay 
(116). The ability of SiPcGal2 and SiPc(OH)2 to generate 1O2 was also determined, 
in order to evaluate the influence of the axial conjugation with dendritic units of 
galactose and the SiPc-core ability in the production of 1O2. SiPcGal4, SiPcGal2 and 
SiPc(OH)2 (0.3 µM), were able to photo-oxidize DPBF (30 µM) (Figure 2.8). Both 
galacto-conjugates demonstrated to be potent generators of 1O2, once SiPcGal4 
and SiPcGal2 were able to decompose 50% of DPBF after 15 min and 7 min of 
irradiation, respectively. The behavior of SiPcGal2 was similar to the one of 
SiPc(OH)2. These results showed that the conjugation of SiPc with protected 
galactose moieties or galacto-dendritic units does not compromise the 1O2 
production. Therefore, these studies showed the promising ability of the SiPc-core 
itself in the generation of this ROS. 
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Figure 2.8. Photo-oxidation of DPBF (30 µM) in DMF with or without SiPcGal4, SiPcGal2 
or SiPc(OH)2 (0.3 µM), after irradiation with red light emitted by a LEDs array (λ > 600 nm, 
5 mW.cm-2). The DPBF absorbance was recorded at 415 nm. 
 
 
2.3 Photostability of the galacto-conjugates 
 
To evaluate the potentiality of the galacto-conjugates as new PSs, it is also 
important to determine their photostability when exposed to UV-Vis light and O2. 
The intensity of the Q band of SiPcGal4, SiPcGal2 and SiPc(OH)2 was monitored 
after irradiation with red light at a fluence rate of 150 mW.cm-2 (Table 2.2). These 
results demonstrated that the three SiPcs are photostable over the irradiation period 
of 30 min. 
 
Table 2.2. Photostability of 20 µM of SiPcGal4, SiPcGal2 and SiPc(OH)2 in PBS (6% 
DMSO), after irradiation with red light at a fluence rate of 150 mW.cm-2 for different periods 
of time (0-30 min). The results are presented in percentage calculated by the ratio of 
residual absorbance (at 683 nm) at different periods of time and absorbance before 
irradiation. 
SiPc 
Irradiation time (min) 
0 1 3 4 5 10 15 20 30 
SiPcGal4 100 93 90 88 85 82 80 79 75 
SiPcGal2 100 98 94 94 94 94 94 94 94 
SiPc(OH)2 100 93 92 91 91 89 86 86 86 
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3. In vitro studies of the galacto-conjugates  
 
3.1 Overview 
 
Pcs are PSs with great photochemical and photophysical properties. Their 
coordination to a silicon atom reduces their aggregation, since its axial 
funcionalization with different bulky groups improves their solubility in a variety of 
solvents. This is directly connected to photosensitizing efficiency as well as fine-
tune fluorescence and triplet state characteristics (52). In Part 2 was possible to 
evaluate those properties, showing that SiPcGal4 and SiPcGal2 were good 
fluorescence labels; stable after light irradiation and efficient generators of 1O2. 
However, as the deprotection of the isopropylidene groups of galactose was not 
achieved in those SiPcs, these compounds demonstrated reduced solubility in PBS. 
In Part 3, it will be evaluated the SiPcGal4 and SiPcGal2 potential as PSs in PDT 
based on uptake, phototoxicity and ROS production after PDT studies in a human 
bladder cancer cell line, UM-UC-3. The potential of SiPcGal4 and SiPcGal2 as PDT 
agents will be compared with the non-galacto-conjugated SiPc(OH)2. UM-UC-3 cell 
line derives from transitional cell carcinoma, which is the most common malignant 
tumor arising from the urothelium. The morphology of these cells is defined by poorly 
adherent, displaying a stellate morphology (117). Additionally, UM-UC-3 BC cells 
exhibit high levels of a galactose-binding protein, galectin-1 (40). 
These studies were performed at the Institute for Biomedical Imaging and 
Life Sciences (IBILI), Faculty of Medicine, University of Coimbra (FMUC). 
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3.2  Uptake of galacto-conjugates by UM-UC-3 bladder cancer cells 
 
 
 
 
 
 
 
 
Scheme 2.5 Chronology of uptake studies performed after incubation of UM-UC-3 BC cells 
with SiPcGal4, SiPcGal2 and SiPc(OH)2. 
  
  
  Based on the fact that UM-UC-3 cells display high levels of Gal-1, we initially 
hypothesized that the presence of the galactose units could facilitate the entry of 
SiPcs into BC cells. However, as discussed in Part 1, galactose-protective groups 
were not successfully removed during their synthesis. Although this fact can 
compromise cellular uptake, we proceeded this work by performing their biological 
evaluation as potential photosensitizing agents for PDT. The BC cells UM-UC-3 
were incubated with 1.66 µM SiPcs in the dark for different periods of time (up to 4 
h) in PBS containing DMSO (less than 0.5%). The fluorescence properties of these 
compounds allowed the evaluation of their intracellular accumulation by quantitative 
spectrofluorimetry and fluorescence microscopy. Each SiPc had different 
fluorescence characteristics, which can be observed in the calibration slopes 
represented in section 3.2.3 of Part 3 in Methods and Materials. The uptake of 
SiPcGal2 and SiPcGal4 was not dependent on the incubation time, probably due to 
their aggregation in PBS (as described in Part 2 of Results and Discussion) as 
well as to their incapacity of interaction with galectin-1 thanks to the galactose-
hydroxyl protective groups. Previous studies with a Pc containing eight dendritic 
units of galactose have demonstrated that its uptake in UM-UC-3 cancer cells is 
dependent on the concentration and reaches a plateau in less than 2 h (40). In the 
present study, the protected galactose molecules axially coordinated with SiPc did 
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not allow that uptake occurs in a both concentration- and uptake time dependent 
manner. Data showed that SiPcGal4 exhibited higher uptake than SiPcGal2 (Figure 
2.9), but these results were inconclusive due to the high aggregation of both SiPcs 
in a PBS containing DMSO (less than 0.5%) solution. Comparing the three SiPcs, 
SiPc(OH)2 had the higher uptake which can be explained by a non-specific 
mechanism caused by reduction of the membrane permeability barrier towards 
amphiphilic SiPc(OH)2. However, there are no records that can sustain this feature. 
Prior studies of SiPcGal2 in a Cremophor EL emulsion showed that this PS have 
high uptake and reaches a plateau after 2 h (45). 
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Figure 2.9. Intracellular accumulation of SiPcGal4, SiPcGal2 and SiPc(OH)2 in UM-UC-3 
cells. (A) Cellular uptake of SiPcGal4, SiPcGal2 and SiPc(OH)2 (1.66 µM) by UM-UC-3 cells 
(in PBS containing 0.5% DMSO), normalized to protein quantity, in function of the uptake 
time (up to 4 h). (B) Representative raw data of fluorescence spectroscopy of BC incubated 
with 1.66 µM SiPcs in the dark, before the normalization to protein concentration. Each SiPc 
has different fluorescence characteristics (see calibration slopes in 3.2.3 of Part 3 in 
Methods and Materials). Data are the mean ± SEM of two independent experiments 
performed in triplicates. 
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  The intracellular accumulation of PSs by UM-UC-3 cancer cells was also 
determined by fluorescence microscopy (Figure 2.10). Cells were incubated with 
1.66 µM of SiPcGal4, SiPcGal2 and SiPc(OH)2 for 3 h (in darkness) and cell nuclei 
were stained with DAPI. The fluorescence of the three PSs was remarkable. 
Fuorescence microscopy confirmed the spectrofluorimetric data showing that cells 
incubated with the three SiPc exhibit occasional bright spots in the perinuclear 
region. Apparently, for both SiPcGal4 and SiPcGal2 red spots were found outside 
the cells (Figure 2.10, A and B), suggesting aggregation of the two galacto-
conjugates. However, acquisition of fluorescence images in bright field could help 
to confirm the intracellular accumulation of the SiPc. Contrary to the other two SiPc, 
SiPc(OH)2 was found throughout the cytoplasm of cancer cells, showing co-
localization with the nuclei (Figure 2.10, C). This could be due to its amphilicity 
relatively to the other two PSs.  
  Previous studies of intracellular fluorescence of SiPcGal2 in a Cremophor EL 
emulsion showed that this Pcs exhibit a co-localization with mitochondria (stained 
with MitoTracker Green FM dye), but not in a exclusively way (45). It would be 
interesting to determine the intracellular location of the three SiPcs using organelle-
specific dyes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Representative fluorescence images of UM-UC-3 cells incubated with 1.66 µM 
of SiPcGal4, SiPcGal2 and SiPc(OH)2 for 3 h in darkness (red) with nucleus stained with 
DAPI (blue). Control fluorescence images (without PS fluorescence) were acquired after 
cells´ incubation with PBS for 3 h in the dark and staining the nucleus with DAPI (blue). 
Scale bars, 20 µm, are indicated on images. Original magnification: 60x. Insets images of 
the three PSs are also represented (A, B and C).  
20 µm 20 µm 20 µm 20 µm 
Control +SiPcGal4 +SiPcGal2 +SiPc(OH)2 
A B C 
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3.3 Dark toxicity and phototoxicity determination of galacto-conjugates in 
UM-UC-3 bladder cancer cells 
 
  A good PS has to be non-toxic until activation by light at a specific 
wavelength. Thus, after confirming the uptake of PSs by UM-UC-3 cancer cells, PSs 
cytotoxicity in darkness was determined. UM-UC-3 cells were incubated with 
increasing concentrations of PSs (0.05 - 1.66 µM) in PBS (containing less than 0.5% 
DMSO) in darkness for 3 h. Cell viability was determined 24 h after treatment by 
MTT colorimetric assay, where the yellow-colored MTT is reduced by mitochondrial 
dehydrogenases in living cells to a formazan precipitate. The formazan absorbance 
is directly correlated with the metabolic activity of living cells. SiPcGal4, SiPcGal2 
and SiPc(OH)2 up to 1.66 µM did not induce significant dark toxicity (Figure 2.11). 
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Figure 2.11. SiPcGal4 (A), SiPcGal2 (B) and SiPc(OH)2 (C) cytotoxicity in the dark in UM-
UC-3 cells. PSs were incubated with different concentrations (0.05 - 1.66 µM, DMSO up to 
0.5%) in UM-UC-3 cells. Cytotoxicity was assessed using MTT colorimetric assay 24 h after 
treatment. The percentage of cytotoxicity was calculated relatively to control cells (cells 
incubated with PBS in darkness). Data are the mean value ± SEM of two independent 
experiments performed in triplicates.  
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Scheme 2.6 Chronology of PDT studies of SiPcGal4, SiPcGal2 and SiPc(OH)2 in UM-UC-
3 BC cells. 
 
  After confirmation of no dark toxicity of the three PSs, the effect of light 
irradiation after SiPcGal4, SiPcGal2 and SiPc(OH)2 uptake on cell viability, MTT was 
performed 24 h after treatment. After PSs uptake in darkness, cells were irradiated 
with red light at a potency of 2.5 mW.cm-2 for 40 min. Control experiments using 
irradiated cells (previously incubated with PBS (containing 0.5% DMSO) for 3 h in 
the dark) were performed, in order to determine the effect of red light irradiation 
alone on cell viability. These conditions did not induce toxicity in the cells. However, 
in the presence of the PSs, there was an increase of the phototoxicity dependent on 
the PS concentration.  
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Figure 2.12. Photocytotoxic effect after SiPc-PDT in UM-UC-3 cells evaluated 24 h after 
PDT. UM-UC-3 BC cells were incubated with increasing concentrations (0.05 - 1.66 µM) of 
SiPcGal4 (A), SiPcGal2 (B) and SiPc(OH)2 (C) for 3 h, in the dark, and then irradiated with 
white light at a fluence rate of 2.5 mW.cm-2 for 40 min. Cytotoxicity was assessed using 
MTT colorimetric assay 24 h after treatment. The percentage of cytotoxicity was calculated 
relatively to control cells (cells incubated with PBS (containing up to 0.5% DMSO) for 3 h in 
darkness and then irradiated). Data are the mean value ± SEM of two independent 
experiments performed in triplicates. *(p < 0.05), **(p < 0.001), ***(p < 0.0001) significantly 
different from control cells. 
 
  
  Among these conditions, SiPcGal4, SiPcGal2 and SiPc(OH)2 presented 
similar ability to induce cell death after PDT with a percentage of toxicity of 18.52, 
28.77 and 26.72 %, respectively, at 1.66 µM. It is expected that only the non-
aggregated fraction of each SiPc would be able to induce cell death, though it is 
necessary to perform this study at higher concentrations or in bio-stable 
formulations. Comparing these results with the ones described in literature, the PSs 
phototoxicity was promising considering the aggregation problem. PcGal16 (Pc 
containing eight deprotected dendritic units of galactose), within the same 
conditions, after 2 h of uptake and at a PS concentration between 0.5 and 2.5 µM, 
the percentage of toxicity was of approximately 50% (2x higher than the SiPcs 
toxicity) (40), showing the great potential of these galacto-conjugated SiPcs to be 
studied in new approaches where the aggregation issue is resolved. Nevertheless, 
these results cannot be compared to the ones of SiPcGal2 in a Cremophor EL 
emulsion, because the conditions were very different: irradiation potency of 40 
mW.cm-2 (16 x higher) and they only used half of the irradiation time. Those results 
showed that a much lower concentration of SiPcGal2 (0.10 µM) was able to 
decrease cell viability by 50% (45). 
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3.4 SiPcGal4, SiPcGal2 and SiPc(OH)2 induced reactive oxygen species 
production after PDT in UM-UC-3 bladder cancer cells 
 
Since it is well established that ROS production has an important role in PDT-
induced cell death, the intracellular production of ROS was evaluated immediately 
after PDT in cells previously incubated with 1.66 µM of the three SiPc for 3 h. In 
order to correlate the PSs’ phototoxicity with ROS production, three different ROS-
sensitive probes: DHE, H2DCFDA and MiyoPy1 (118-120) were used. DHE is able 
to react with O2·⁻ and be oxidized to ethidium, which intercalates within the cell’s 
DNA, staining the nucleus with bright red fluorescence. H2DCFDA reacts with 
several cytotoxic ROS leading to the formation of the fluorescence compound DCF. 
Finally, MitoPy1 selectively tracks to the mitochondria and responds to local fluxes 
of H2O2 by a turn on fluorescence enhancement. 
First, UM-UC-3 cells were incubated for 3 h with PBS (control) or 1.66 µM of 
SiPcGal4, SiPcGal2 and SiPc(OH)2, in darkness and then they were irradiated for 
40 min. None of the SiPcs tested induced a high production of ROS after PDT 
(Figure 2.13). Regarding SiPcGal4, this PS did not showed an increase in the O2·⁻ 
production, but the generation of H2O2 and total ROS was significant. SiPcGal2 and 
SiPcOH2 showed, after PDT, a significant increase in the production of O2·⁻, H2O2 
and total ROS. Once again, it is expected that only the non-aggregated fraction of 
each SiPc would be able to produce ROS, though it is necessary to perform this 
study at higher concentrations or in bio-stable formulations. SiPcGal2 in a 
Cremophor EL emulsion showed high production of ROS levels as determined using 
DCFDA probe (109). 
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Figure 2.13. Quantification of DHE (A), DCF (B) and MitoPy1 (C) fluorescence increase 
(as a measure of ROS production) after PDT with SiPcGal4, SiPcGal2 and SiPc(OH)2. UM-
UC-3 cells were incubated with PBS (control) or 1.66 µM of SiPcGal4, SiPcGal2 or 
SiPc(OH)2 for 3 h in the dark. After PDT during 40 min, the fluorescent signals of the probes 
were quantified by fluorescent spectroscopy. Data are the mean value ± SEM of two 
independent experiments performed in triplicates. *(p < 0.05), **(p < 0.001), ***(p < 0.0001) 
significantly different from control cells. 
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III. Conclusions and future perspectives 
 
In this Master’s dissertation, we attempted the synthesis of symmetrical water 
soluble SiPcs axially coordinated with galacto-dendritic units. We also aimed the 
removal of the isopropylidene galactose-protective groups from the already 
described in the literature, SiPc axially conjugated with two galactose moieties 
(SiPcGal2), so that we can have a comparative compound. These galactose 
molecules will be recognized by galectins (galactose-binding proteins), 
overexpressed in bladder tumors. Thus, after the drug design, the following step 
was to study their photophysical and photochemical properties, and to validate them 
as photodynamic therapeutic agents against BC cells.  
 
The preparation of the two SiPc axially conjugated with galacto-dendritic units 
was partially achieve once it was only possible to perform the coordination step of 
the SiPc dichloride (SiPcCl2) with the protected galacto-dendritic units containing 
the 1,3-propanediol chain (SiPcGal4). Additionally, our several attempts to 
hydrolyze the isopropylidene groups of the galactose molecules in either the 
SiPcGal4 or SiPcGal2 failed. However, a new galacto-dendritic unit [3] was obtained 
and in future work, different approaches could be used to then produce the desired 
final PS. One methodology that can be applied is to first hydrolyze the 
isopropylidene groups of compound 3, with TFA/water (9:1) and then conjugate it 
with the SiPcCl2 in a reflux DMF reaction. Other route than we can undergo is to 
hydrolyze the isopropylidene groups of compound 1 and then conjugate it with 
SiPc(OH)2 in a reflux DMF reaction with potassium carbonate (K2CO3). Finally, to 
obtain SiPcGal2 with the deprotected galactose molecules, we can conjugate the 
commercially available D-(+)-galactose with SiPcCl2 also in a reflux DMF reaction 
with K2CO3. However, it is possible that we will be confronted with solubility issues 
to perform these reactions. 
 
Regarding the photophysical and photochemical studies, both galacto-
conjugates were also compared with SiPc dihydroxide (SiPc(OH)2) in order to 
understand if the SiPc core properties are useful for future drug design. SiPcGal4 
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and SiPcGal2 containing the isopropylidene groups demonstrated some particular 
properties that allowed us to predict the behavior of these macrocyclic cores. Of 
course there were some issues on their hydrophilicity under physiological 
conditions, which are fundamental for drug administration. Yet, in comparison with 
the SiPc(OH)2, their water solubility was higher due to the presence of axial 
substituents that reduced their aggregation. Thus, if the isopropylidene goups’ 
hydrolysis was successfully accomplished, the solubility would be much higher. The 
typical spectra of this SiPcs contained a strong Q-band absorption at around 670 
nm (therapeutic window), which allows deeper tissue penetration upon light 
irradiation. Both PSs also demonstrated to be good 1O2 generators and photostable 
upon 30 min of irradiation, which showed their high capacity to be used as PDT 
agents. Determination of the galacto-conjugates affinity to HSA and galectin-1 
proteins could be an interesting approach to perform if we were successful in the 
hydrolysis of the galactoses’ protective groups. HSA is a blood protein that is able 
to transport many drugs to the effector place demonstrating their ADME properties 
and galectin-1 is a galactose-binding protein overexpressed in BC cells.  
 
For the in vitro photodynamic assays, a human bladder cancer cell line, UM-
UC-3, derived from the transitional cell carcinoma of the bladder was used. The 
uptake of the two galacto-conjugates was lower than the uptake of the SiPc(OH)2. 
This feature resulted from non-specific mechanism caused by reduction of the 
membrane permeability barrier towards amphiphilic SiPc(OH)2. However, the PSs 
uptake was not correlated with the concentration and incubation time increment, due 
to their high aggregation in PBS solution, leaving the results inconclusive. The 
fluorescence microscopy study suggested that aggregation outside of the cells may 
occur, but on the other hand, it was clear their outstanding fluorescence properties.  
SiPcGal4 and SiPcGal2 were non-toxic in the dark but after photoactivation, 
they induced a significant decrease in cell viability. However, once these SiPcs 
aggregate in cells, it was expected that only a fraction of the administered Pc (non-
aggregated fraction) will induce cell death, thus being difficult to interpret these 
results.  
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The PSs-induced ROS after PDT were also studied and showed an increase 
of the H2O2 present in the mitochondria and also of other general ROS in the 
cytoplasm. If these results were from the deprotected SiPcGal4 and SiPcGal2, the 
next step could be studies of fluorescence microscopy using different fluorescent 
probes to study co-localization of the new PSs with different organelles. Another 
study that could be performed if we had the desired compounds, is the 
immunofluorescence staining of Gal-1 to observe the subcellular localization of this 
lectin and the galacto-conjugates in BC cells, and their possible co-localization. 
Specific inhibition of galectin-1 expression by RNAi (interference ribonucleic acid) 
could also be an approach to be used in future works, in an attempt to investigate 
the involvement of this protein in the uptake of the PSs BCa cells. 
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1. Synthesis of galacto-phthalocyanines 
 
1.1 Equipment, materials and reagents 
 
1.1.1 Equipment and materials 
Flash column chromatography was carried out with silica gel Merck-60 (230-
400 mesh, 0.040-0.063 mm) and size exclusion chromatography by Biorad, 
Biobeads SX-1. Analytical Thin Layer Chromatography (TLC) on pre-coated sheets 
with silica gel 60 F254 or 60 ReversePhase-18 F254 S were from Merck. Reverse 
phase column chromatography was carried out using Sep-Pak®Vac 35 cc (10 g) 
columns. 
NMR spectra (1H and 13C) were recorded with a Bruker AV-300 (300 MHz) 
instrument. Deuterated solvents used are indicated in brackets and 
tetramethylsilane (TMS) was used as internal reference. The chemical shifts () are 
expressed in ppm and the coupling constants (J) in Hz. Maldi-MS were obtained in 
positive ion mode from an Applied Biosystem 4700 instrument or a Bruker Ultraflex 
III TOFTOF both equipped with a Nd:YAG laser operating at 355 nm and were 
carried out at Servicio Interdepartamental de Investigación (SIdI) of the University 
Autónoma of Madrid.  
 
1.1.2 Reagents and chemical products 
SiPcCl2, 1,2:3,4-di-O-isopropylidene-α-D-galactopyranose, 1,3-propanediol, 
1,3-dimercaptopropane, TCT, NaH and pyridine were obtained from Sigma-Aldrich. 
DMF, DCM, Hex, AcOEt, tetrahydrofuran (THF), MeOH, DIPEA and toluene 
were purchased from Fisher Scientific. 
TFA and TMSBr are from Tokyo Chemical Industry (TCI) and sodium 
bicarbonate (NaHCO3) from Merck. 
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1.1.3 Software 
ChemDraw Ultra 14.00 from CambridgeSoft was the software used to draw 
the chemical structures. MestReNova LITE was used to analyze the 1H and 13C 
NMR spectra. 
 
 
1.2  Experimental procedures 
 
1.2.1 Galacto-dendritic units synthesis 
 
A. Synthesis of 2-chloro-4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-galactopyran-6-
yl)-1,3,5-triazine [1] (72) 
 
Compound 1 (2-chloro-4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-
galactopyran-6-yl)-1,3,5-triazine) was synthesized as previously described in 
literature. 1,2:3,4-di-O-isopropylidene-α-D-galactopyranose (3.0 g, 11.60 mmol) 
was dissolved in dry toluene (30 mL) and a large excess of DIPEA (4.0 mL) was 
added. The reaction was then cooled at 0 ºC and TCT (1.1 g, 5.80 mmol) was added 
to the mixture. The reaction was stirred at 60 ºC during 72 h, under Ar. After 
concentration under vacuum, the residue was purified by flash gradient column 
chromatography on silica gel, by using Hex:AcOEt (8:2 to 7:3 v/v) as eluent, 
affording compound 1 as a white solid (2.43 g, 66%). 1H NMR (300 MHz, CDCl3):  
1.31, 1.32, 1.44 and 1.49 (4s, 4 x 6H, CH3), 4.18 (ddd, 4H, J4’-5’= 1.4, J5’-6’a = 6.4, J5’-
6’b = 6.5 Hz,  H-5’), 4.30 - 4.33 (m, 4H, H-2’, H-4’), 4.53 (m, 4H, H-6’a and H-6’b), 
4.62 (dd, 4H, J2’-3’ = 7.9, J3’-4’ = 2.4 Hz, H-3’) and 5.52 (d, 2H, J1’-2’ = 5.0 Hz, H-1’) 
ppm. 
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B. Synthesis of 3-[(4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-galactopyran-6-yl)-
1,3,5-triazin-2-yl)thio]propane-1-thiol [2] (72) 
 
Compound 2 (3-[(4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-galactopyran-6-
yl)-1,3,5-triazin-2-yl)thio]propane-1-thiol) was synthesized as previously described 
in literature. Compound 1 (0.50 g, 1.58 mmol) was dissolved in dry toluene (9.0 mL). 
DIPEA (0.69 mL, 7.90 mmol) and 1,3-dimercaptopropane (0.25 mL, 6.32 mmol) 
were then added and the mixture stirred at 70 ºC during 48 h, under Ar. After 
concentration under reduced pressure, the residue was purified by column 
chromatography on silica gel, using a mixture of Hex/AcOEt (7:3 to 6:4 v/v) as 
eluent. The desired compound 2 was obtained as a viscous colorless oil (0.44 g, 
89%). 1H NMR (300 MHz, CDCl3):  1.31, 1.32, 1.44 and 1.49 (4s, 4 x 6H, CH3), 
2,02 (m, 2H, CH2CH2CH2SH), 2.64 (m, 2H, CH2CH2CH2SH), 2.75-2.80 (m, 1H, SH), 
3.23 (m, 2H, CH2CH2CH2SH), 4.17 (ddd, 4H, J4’-5’= 1.7, J5’-6’a = 4.8, J5’-6’b = 6.9 Hz, 
H-5’), 4.30-4.34 (m, 4H, H-2’, H-4’), 4.50 (m, H-6’a and H-6’b), 4.61 (dd, 4H, J2’-3’ = 
7.7, J3’-4’ = 2.3 Hz, H-3’) and 5.52 (d, 2H, J1’-2’ = 4.7 Hz, H-1’) ppm. MS (ESI+, MeOH 
+ 0.1% formic acid) results were: m/z calculated for C30H45N3O12S2 [M+H]+: 704.24 
found: 704.25. 
 
C. Synthesis of 3-[(4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-galactopyran-6-yl)-
1,3,5-triazin-2-yl)oxi]propane-1-diol [3] 
 
Under Ar, compound 1 (720 mg, 1.14 mmol) was dissolved in dry toluene (9.0 
mL) and then it was added DIPEA (0.55 mL, 5.72 mmol) and 1,3-propanediol (0.46 
mL, 5.72 mmol). The mixture was stirred at 80 ºC during 72 h. After concentration 
under vacuum, the residue was purified by column chromatography on silica gel, 
using a mixture of Hept:AcOEt (6:4 to 1:1 v/v) to afford compound 3 (471 mg, 61%) 
as a viscous yellow oil. 1H NMR (300 MHz, CDCl3):  1.31, 1.32, 1.44 and 1.49 (4s, 
4 x 6H, CH3), 1.99 (m, 2H, CH2CH2CH2OH), 3.76 (m, 2H, CH2CH2CH2OH), 4.18 
(ddd, 2H, J4’-5’= 1.8, J5’-6’a = 6.5, J5’-6’b = 6.6 Hz, H-5’), 4.30-4.35 (m, 4H, H-2’, H-4’), 
4.51 (m, 4H, H-6’a and H-6’b), 4.54 (m, 2H, CH2CH2CH2OH), 4.61 (dd, 4H, J2’-3’ = 
8.4, J3’-4’ = 2.4 Hz, H-3’) and 5.52 (d, 2H, J1’-2’ = 5.0 Hz, H-1’) ppm. MS (ESI+, MeOH 
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+ 0.1% formic acid) results were: m/z calculated for C30H45N3O14 [M+H]+: 672,29 
found: 672.30.  
 
1.2.2 Coupling of SiPcCl2 with galacto-dendritic units 
 
A. Synthesis of SiPc 4 [SiPcGal2] (45) 
 
SiPcGal2 was afforded following a procedure described in the literature by 
reacting SiPcCl2 (163 mg, 0.225 mmol) with 1,2:3,4-di-O-isopropylidene-α-D-
galactopyranose (118 mg, 0.454 mmol) and  NaH (67 mg, 0.897 mmol). The 
reaction mixture was put in toluene reflux at 120 ºC during 48 h, under Ar. After 
concentration under vacuum, the crude product was purified by column 
chromatography on silica gel using a mixture of Hex/AcOEt (7:3 v/v) as eluent and 
then collected as a blue solid (126 mg, 53%). 1H NMR (300 MHz, CDCl3):  -2.37 
(dd, 2H, J = 8.8, 9.3 Hz, OCH), -1.70 (dd, 2H, J = 5.3, 8.3 Hz, OCH), 0.30 (s, 6H, 
Me), 0.49 (s, 6H, Me), 0.68 (virtual s, 8H, Me and H-5’), 0.76 (dd, 2H, J = 1.0, 8.2 
Hz, H-4’), 0.79 (s, 6H, Me), 3.22 (dd, 2H, J = 1.5, 8.5 Hz,H-3’), 3.32 (dd, 2H, J = 1.6, 
5.4 Hz, H-2’), 4.37 (d, 2H, J = 5.0 Hz, H-1’), 8.28-8.31 (m, 8H, Pc–Hβ) and 9.59-9.62 
(m, 8H, Pc–Hα) ppm. MS (MALDI, DCTB+NaI) results were: m/z calculated for 
C56H54N8O12Si [M]+: 1058.4 found: 1058.4. 
 
B. Failed attempt of synthesis of SiPc 5 
 
The SiPcCl2 (30 mg, 0.049 mmol) and dendritic unit 2 (100 mg, 0.142 mmol) 
were dissolved in DMF (2.5 mL), and the reaction stirred at 120 ºC for 24 h, under 
Ar. After evaporating the solvent the crude product was purified by column 
chromatography using DCM/Hex (3:1 to 1:0 v/v) and then DCM/MeOH (80:1 to 60:1 
v/v) as eluents. The collected fraction was further purified by BioBeads (DCM). The 
obtained product had a blue color. The 1HNMR spectrum didn’t show any sugar 
characteristic signals and MS (MALDI, DCTB+NaI) results were: m/z calculated for 
C92H104N14O24S4Si [M+H]+: 1946 found: 574 (SiPc(OH)2).  
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C. Synthesis of SiPc 6 [SiPcGal4] 
 
SiPcGal4 was prepared by a reaction between SiPcCl2 (67 mg, 0.0934 
mmol), compound 3 (300 mg, 0.447 mmol) and a large excess of pyridine (0.2 mL). 
The compounds were dissolved in 12 mL of toluene and the mixture refluxed 
overnight. After elimination of the solvent under vacuum, the residue was purified 
by column chromatography on silica gel Hex:AcOEt (3:2 to 1:1 v/v) affording 
SiPcGal4 as a blue solid (30 mg, 12%). 1H NMR (300 MHz, CDCl3):  -1.99 (t, 4H, 
J = 6.5 Hz, CH2CH2CH2OSi), -1.06 (m, 4H, CH2CH2CH2OSi), 0.00 (t, 6H, J = 3.9 Hz, 
CH2CH2CH2OSi), 1.38, 1.41, 1.54 and 1.55 (4s, 4 x 12, CH3), 4.22 (ddd, 4H, 8H, J4’-
5’= 1.0, J5’-6’a = 4.0, J5’-6’b = 4.0 Hz, H-5’), 4.32 (m, 4H, H-4’), 4.39 (m, 4H, H-2’), 4.42 
(m, 8H, H-6’), 4.69 (dd, 4H, J2’-3’ = 4.7, J3’-4’ = 1.4 Hz, H-3’), 5.64 (d, 4H, J1’-2’ = 2.9 
Hz, H-1’), 8.29-8.31 (m, 8H, Pc–Hβ) and 9.55-9.57 (m, 8H, Pc–Hα) ppm. 13C NMR 
(CDCl3):  24.5, 25.0, 26.1 and 26.2 (Me-isop), 27.8 (CH2CH2CH2OSi), 52.6 
(CH2CH2CH2OSi), 65.5 (CH2CH2CH2OSi), 66.0 (C-5’), 70.7 (C-6’), 76.8 (C-3’), 77.0 
(C-2’), 77.3 (C-4’), 96.4 (C-1’), 96.4, 107.9, 108.8, 109.5, 114.4, 123.6, 129.7, 130.9, 
131.0, 135.8, 137.7 (Pc-Cβ), 139.1, 139.5, 140.1, 149.2 (Pc-Cα), 165.3 (C-4, C-6, 
TCT) and 172.2 (C-2, TCT) ppm. MS (MALDI, DCTB) results were: m/z calculated 
for C92H104N14O28Si [M+H]+:1881.7 found: 1881.6. 
 
1.2.3 Failed attempts of deprotection of the isopropylidene groups 
 
A. Deprotection of isopropylidene groups in SiPcGal4 and SiPcGal2 using 
TFA/water (9:1) 
 
SiPcGal4 (20 mg, 0.0189 mmol) and SiPcGal2 (20 mg, 0.0106 mmol) in 
TFA/water (9:1 v/v, 5 mL) were stirred at rt during 5 h. The mixture was neutralized 
with an aqueous solution of NaHCO3 (pH=7.0) and the product was purified by 
reverse phase column chromatography on silica gel (THF/H2O, 7:3 v/v) as eluent. 
Both compounds were then precipitated with DCM, filtered, washed with acetone 
and dried under reduced pressure.  
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Deprotected SiPcGal2 MS (MALDI, DCTB+NaI) results were: m/z calculated for 
C44H38N8O12Si [M]+: 898.2, found: 574.2 (SiPc(OH)2). 
Deprotected SiPcGal4 MS (MALDI, DCTB+NaI) results were: m/z calculated for 
C68H72N14O28Si [M]+: 1560.4, found: 574.2 (SiPc(OH)2). 
 
B. Deprotection of isopropylidene groups in SiPcGal4 and SiPcGal2 using TMSBr 
 
SiPcGal4 (10 mg, 0.0473 mmol) and SiPcGal2 (10 mg, 0.00531 mmol) were 
dissolved in DCM and then it was added TMSBr (0.473 and 0.0531 mmol, 
respectively) and stirred at rt overnight. The products were precipitated with DCM, 
filtered, washed with acetone and dried under reduced pressure.  
Deprotected SiPcGal2 MS (MALDI, DCTB+NaI) results were: m/z calculated for 
C44H38N8O12Si [M]+: 898.2, found: 574.2 (SiPc(OH)2). 
Deprotected SiPcGal4 MS (MALDI, DCTB+NaI) results were: m/z calculated for 
C68H72N14O28Si [M]+: 1560.4, found: 574.2 (SiPc(OH)2). 
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2. Photophysical and photochemical studies of galacto-
conjugates 
 
2.1 Equipment and reagents 
 
2.1.1 Equipment 
The UV-visible assays were performed on the UVIKON 922 
spectrophotometer from Biotek Instruments.  
The illumination system used to determine the photostability of the PSs was 
the Light Source Model LC-122 from LumaCare, equipped with a halogen/quartz 
250 W lamp coupled to one optic fiber probe (400-800 nm). The fluence rates were 
determined with the energy meter Coherent FieldMaxII-Top with a Coherent 
PowerSens PS19Q energy sensor. 
For the 1O2 generation study it was used a Light Emitting Diode (LED) array 
prepared by Mr. Cândido Casqueira, electromechanic technician of the Department 
of Chemistry of the University of Aveiro. It is composed of a matrix of 6 x 8 LEDs 
which makes a total of 48 light sources, emitting red light (λ > 600 nm). The regulated 
Plug-in adaptor with LED indicator 800 mA was purchased from Mean Well (MW). 
 
2.1.2 Reagents, chemical products and buffers 
SiPcGal4, SiPcGal2 and SiPc(OH)2 were synthesized as described in Part 1. 
DMSO, DMF and DPBF were obtained from Fisher Scientific. PBS buffer was 
prepared in Milli-Q water at pH 7.60: 10 mM NaH2PO4, 70 mM Na2HPO4 and 145 
mM NaCl. 
 
2.1.3 Softwares 
Microsoft Excel and GraphPad Prism 5.00 were used for the displayed 
graphs. 
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2.2 Experimental procedures 
 
2.2.1 Aggregation assays 
 
The aggregation behavior of the PSs in PBS buffer, DMSO and DMF was 
studied at different concentrations by Lambert-Beer´s law plots. This equation is 
based on the linear correlation between absorbance (A), molar absorptivity of the 
compound (ɛ, L.mol-1.cm-1), length of the light path (b, cm) and concentration of the 
compound in solution (c, mol.L-1) (121). 
First, stock solutions of the galacto-conjugates (330 µM) were prepared in 
DMSO and frozen. The working solutions were freshly prepared by diluting the stock 
solutions in PBS buffer (1.25-10 µM) with the concentration of DMSO being always 
inferior to 3% (v/v). Quartz cuvettes holding one milliliter of working solutions 
(without air bubbles) were placed into the spectrophotometer and the absorbance 
was scanned for wavelengths between 300 to 800 nm. The wavelengths of 
maximum absorption were determined and the molar absorptivity of the compounds 
was calculated by plotting the absorbance against the respective concentration, by 
Lambert -Beer´s law, considering the length of the light path (b) equal to 1 cm. The 
same procedure was performed with the compounds dissolved in complete DMSO 
and DMF. 
 
2.2.2 Fluorescence emission assay 
 
SiPcGal4, SiPcGal2 and SiPc(OH)2 working solutions were freshly prepared 
in DMF to give absorbance near 0.03 (conditions that minimize reabsorption of 
radiation by the ground-state species) at 601 nm. The fluorescence emission 
spectra of the PSs were measured between 620 to 800 nm, after excitation at 601 
nm. The excitation and emission slits width were set at 2.0 nm.  
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2.2.3 Photostability assays 
 
The photostability of PSs was determined by monitoring the decrease of the 
absorbance of Q bands, after different times of irradiation with red light (400-800 
nm) delivered by an illumination system. Solutions of PSs at 20 µM were prepared 
in PBS buffer (6% v/v DMSO) and kept in the dark at rt. The study was performed 
in magnetically stirred cuvette solutions (with 1 mL of sample) in a dark room, over 
an irradiation time of 30 min with red light at a fluence rate of 150 mW.cm-2. The 
absorbance between 640 and 730 nm (Q band that corresponds to the maximum 
absorbance of PSs) was determined before and after irradiation (1, 3, 4, 5, 10, 15, 
20 and 30 min). After that, the photostability percentage was calculated with the 
following equation: 
 
𝑃ℎ𝑜𝑡𝑜𝑠𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝐴𝑏𝑠 𝑎𝑡 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑖𝑟𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛
𝐴𝑏𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝑖𝑟𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛
 
 
2.2.4 Singlet oxygen assays 
 
Singlet oxygen was determined through an indirect chemical method using 
DPBF as 1O2 scavenger (122). The DPBF reacts specifically with 1O2 in a [4+2] 
cycloaddition reaction, being oxidized to the colorless o-dibenzoylbenzene. Once 
DPBF has an absorption maximum at 415 nm, the ability of the PSs to generate 1O2 
is obtained by measuring the DPBF absorption decay, at this wavelength. 
 
 
Scheme 4.1. Reaction of DPBF with 1O2 by a Diels Alder reaction. 
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Solutions containing DPBF (30 µM) with or without the PSs (0.30 µM) were 
prepared in DMF in a one milliliter quartz cuvette. The solutions were irradiated at rt 
and under gentle magnetic stirring, with red light at a fluence rate of 5 mW.cm-2. The 
decreasing of DPBF absorbance value at 415 nm was monitored at pre-established 
irradiation intervals. The results were expressed by plotting the DPBF depletion 
against the irradiation time. The depletion of DPBF was calculated according to the 
following equation:  
 
𝐷𝑃𝐵𝐹 𝑑𝑒𝑝𝑙𝑒𝑡𝑖𝑜𝑛 =  
𝐴𝑏𝑠𝑡
𝐴𝑏𝑠0
 
Abs0 and Abst are the absorbance values at 415 nm before and after 
irradiation, respectively. 
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3. In vitro biological studies 
 
3.1 Equipment, materials and reagents 
 
3.1.1 Equipment 
The centrifuge used was a SIGMA 2-16 and the microcentrifuge was a VWR 
MiniFuge Galaxy MiniStar C1413. The vortex was from VWR. The liquid aspirator 
system used was the Vacusip from Integra. The shaker used was a standard analog 
shaker from VWR. 
The UV-visible absorbance measurements were performed on a microplate 
reader Synergy™ HT (Biotek Instruments) controlled by BioTek's Gen5™ Data 
Analysis Software. The fluorescence measurements were determined using the 
Typhoon FLA 9000 in combination with its Image Quant TL software. 
Photodynamic irradiation was carried out with red light (620-750 nm) 
delivered by an illumination system (LC-122 LumaCare, London). The light was 
delivered for 40 min at a fluence rate of 2.5 mW/cm2, as measured with an energy 
meter (Coherent FieldMaxII-Top) combined with a Coherent PowerSens PS19Q 
energy sensor. 
The fluorescence microscope was purchased from Leica DFC350 FX, Leica 
Microsystems, Bannockburn, IL, USA. 
 
3.1.2 Materials 
Canted neck cell culture flasks 75 cm2 with 0.2 µM vent cap were purchased 
from Corning. CyroPure tubes were purchased from SARSTEDT. The tissue culture 
test plates and the conical tubes of 15 mL or 50 mL were from Orange Scientific. 
The Neubauer chamber was from VWR. The plates used were transparent (Orange 
Scientific) and black (Greiner Bio -One) 96-wells microtiter plates for the absorbance 
and fluorescence studies, respectively. 
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3.1.3 Cell culture/trypsin/kit/probes 
UM-UC-3 (ATCC® Number: CRL-1749TM), human bladder transitional 
carcinoma cell line, have been isolated from urinary bladder of a male caucasian. 
Roswell Park Memorial Institute (RPMI)-4130 medium (Sigma) 
supplemented with 2 gL-1 sodium bicarbonate (Sigma), 2 mM L-glutamine (Sigma), 
10% (v/v) of heat-inactivated Fetal Bovine Serum (FBS; Life Technologies, 
Carlsbad, CA, USA) and antibiotic/antimycotic containing 100 unitsmL-1 penicillin, 
100 µgmL-1 streptomycin and 0.25 µgmL-1 amphotericin B (Sigma). 
Trypsin Tryple Express was purchased from Gibco (Ref. 12605-010). 
The Pierce BCA Protein Assay Kit-Reducing Agent Compatible (containing 
the BCA Protein Assay Reagent and bovine serum albumin (BSA) standards at 2 
mg.mL-1) was purchased from Thermo Scientific. 
The 4′,6-Diamidino-2-phenylindole (DAPI) was purchased from Enzo Life 
Sciences. The H2DCFDA (2’,7’-dichlorohydrofluorescin) and DHE (dihydroethidium) 
were purchased from Life Sciences. MiyoPy1 (Mitochondria peroxy yellow 1) was 
obtained by Sigma-Aldrich. 
 
3.1.4 Reagents, chemical products and buffers 
SiPcGal4, SiPcGal2 and SiPc(OH)2 were synthesized as described in Part 1. 
 Paraformaldehyde (PFA) was from Merck and sodium dodecyl sulfate (SDS) 
and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were 
purchased from Sigma-Aldrich. 
 The trypan blue stain 0.4% was from BioWhittaker Reagents, Lonza. The 
hydrochloric acid (HCl) 37% was from Panreac. 
 The VectaSHIELD mounting medium with DAPI was purchased from 
VECTOR. 
PBS buffer is composed of 137 mM NaCl, 27 mM KCl, 81 mM Na2HPO4, 15 
mM KH2PO4 and is prepared in Milli-Q water. 1% SDS lysis buffer has 1% (v/v) SDS. 
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3.1.5 Softwares 
Paint Shop ProTM (v.6.00, Jasc Software) was used for the treatment of the 
images obtained in microscopy. GraphPad Prism (v.5.00, GraphPad Software) was 
used for most of the displayed graphs, as well as for the statistical analysis. 
 
3.1.6 Statistical Analysis 
The results are presented as mean ± standard error of the mean (S.E.M.) 
with n indicating the number of experiments. Statistical significance among two 
conditions was assessed using the nonparametric Mann-Whitney test. Statistical 
significance among three conditions was assessed by the nonparametric Kruskal-
Wallis test. Statistical significance among several conditions was assessed with the 
Friedman test. P-value was considered at the 5% level of significance to deduce 
inference of the significance of the data. 
 
3.2 Experimental procedures 
 
3.2.1 Cell culture and subculture 
 
 UM-UC-3 cells were grown in RPMI medium. After two to three days, 
confluent cells were subcultured. The medium was removed from culture flasks by 
aspiration and discarded. The cell layers were washed with 10 mL of pre-warmed 
sterile PBS, in order to remove traces of FBS that would inhibit the action of the 
trypsin. After that, the cells were treated with 2.5 mL of trypsin Tryple Express and 
incubated during 5 min at 37 ºC until the cells rounded up and the cell layer start to 
disperse. The trypsinization progress was monitored under an inverted microscope. 
After incubation, RPMI medium was added to inhibit further tryptic activity and the 
cells were dispersed by repeated pippeting over the monolayer surface. The cells 
suspensions were then centrifuged at 1,000 x g for 5 min. The supernatant was 
removed, the cells were re-suspended in RPMI medium and appropriate aliquots of 
cells were added to new 75 cm2 culture flasks. Cells were examined carefully every 
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day by eye on an inverted microscope, for signs of contamination and the RPMI 
medium was changed two or three times per week (118). 
 
3.2.2 Preparation and treatment of UM-UC-3 cells with photosensitizers  
 
After the removal of supernatant and the re-suspension of the cells in 10 mL 
of RPMI medium as described before, 20 µL of cell suspension was mixed with 20 
µL of trypan blue stain to determine cellular viability. Trypan Blue is an organic 
amine dye that is excluded by living cells with intact membranes, while death cells, 
where the plasma membrane integrity is compromised, take up the dye. Thus, all 
the cells that are blushed with the dye are considered non-viable and appear with a 
blue color in the microscope. On the other hand, viable cells will appear brilliant. 
Cells were counted using a haemocytometer. The percentage of viable cells and the 
concentration of cells per milliliter of cell suspension were calculated according to 
the following equations: 
 
𝑉𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 (%) =
𝑁º 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
𝑁º  𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠
 × 100 
 
𝑉𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
=
𝑉𝐶𝑠 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
1 × 10−4
 
 
Only cells with viability superior to 90% were utilized in the experiments. The viable 
cells concentration was calculated considering the average of viable cells (VCs) per 
each counting square, the dilution made and the volume of each counting square. 
After this, UM-UC-3 cells were seeded into cell culture plates of 24 or 96-
wells according to the experiment, at a density of 18 x 104 and 3 x 104 cells.cm-2 
respectively, and incubated overnight in an incubator at 37 ºC with 5% CO2 and 95% 
air to promote cell adhesion. On the following day, the UM-UC-3 cells growing in 
monolayer culture were treated with desired concentrations of sterile solutions of 
PSs.  
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Stock solutions of the PSs at a concentration of 330 µM were prepared in 
sterile DMSO and stored at 0-4 ºC in dark conditions. Freshly working solutions with 
different concentrations were obtained from the respective stock solution in sterile 
PBS, accounting their water solubility range. The concentration of DMSO was 
always lower than 0.5% (v/v), in all working solutions. 
 
3.2.3 Determination of intracellular PS concentration by fluorimetry 
 
Taking into account the fluorescence properties of the Pcs, their 
concentration inside the cancer cells can be determined by fluorimetry (after cell 
lysis) and normalized to total protein quantity. The protein quantification was 
measured spectrophotometrically using the Bicinchoninic Acid Assay (BCA assay), 
also known as the Smith assay (123). The procedure involves two fundamental 
steps: 1) biuret reaction, where the cupric ion (Cu2+) is reduced to cuprous ion (Cu+) 
by peptide bonds in proteins, in an alkaline environment, resulting in a blue color, 
and therefore, the amount of reduced Cu2+ is proportional to the amount of protein 
present in the solution; 2) the chelation of two molecules of BCA with one cuprous 
ion results in an intense purple-colored product that can be measure at any 
wavelength between 550 nm and 570 nm. 
 
A. Determination of intracellular PS fluorescence 
 
UM-UC-3 cells were seeded into 96-wells cell culture plates at a density of 3 
x 104 cells per well (final volume of 100 µL per well) and incubated overnight in an 
incubator at 37 ºC with 5% CO2 and 95% air. On the following day, immediately after 
PSs incubation, cells were washed twice with PBS. Then, they were mechanically 
scrapped in 120 µL of 1% (m/v) SDS solution in PBS (pH 7.0) and the plate was 
stirred on an automatic plate shaker in the dark at rt. 90 µL of this cell suspension 
were transferred to 96-wells black plates and the intracellular fluorescence of the 
PSs was determined by fluorometric measurement, using standard PSs solutions (0 
– 6.25 µM) for calibration (Figure 4.1). The intracellular fluorescence was 
determined using a Typhoon FLA 9000 imager (GE Healthcare) with a 100-µm spot 
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resolution and 300 V. The excitation and emission wavelengths were set at 635 nm 
(red LD laser) and LPR (665LP), respectively. The PS concentration in the samples 
was directly obtained by plotting the average of the fluorescence for each PS 
standard in function of its concentration (µM). The results were normalized for 
protein concentration.  
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Figure 4.1 Calibration slopes of the PSs (SiPcGal4 (A), SiPcGal2 (B) and SiPc(OH)2 (C)) 
fluorescence average in function of their standard concentrations (0 - 6.25 µM). 
 
B. Determination of protein concentration 
 
In a 96-wells plate, the following solutions were pipetted into each well: 
- 25 µL of sample buffer: 1% (m/v) SDS in PBS (pH 7.0), 
- 25 µL of sample, blank (sample buffer), standard (prepared in the sample 
buffer at concentrations ranging from 12.5-800 µg.mL-1 using the BSA standard at 2 
mg.mL-1), 
- 150 µL of BCA working Reagent (50 parts of BCA reagent A mixed with one 
part of BCA reagent B). 
The plate was incubated at 37 ºC for 30 min. Then, the absorbance at 570 
nm was measured in the plate reader spectrophotometer. The protein concentration 
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in the samples was directly obtained by plotting the average of the absorbance at 
570 nm for each BSA standard in function of its concentration (µg.mL-1). 
 
3.2.4 Determination of intracellular PS fluorescence by fluorescence 
microscopy 
 
Knowing the fluorescence properties of Pcs, their intracellular fluorescence 
can also be evaluated by fluorescence microscopy. Coverslips (one per well in 24-
wells culture plates) were coated with poly-L-lysine for 1 h at rt. Then, after drying 
completely the UM-UC-3 were plated at a density of 18 x 104 cells per well (200 µL 
per well), in 24-wells culture plates for 3 h before treatment. After PS uptake and 
washing, cells were fixed with 4% PFA for 10 min at rt. The samples were washed 
with PBS (2 x 5 min). The coverslips were mounted using Vectashield sealed with 
nail polish and stored at 4 ºC until visualization under the fluorescence microscope. 
 
3.2.5 Photodynamic Assays 
 
The desired effect that is expected to obtain after photo-activation of PS is 
not only its preferential accumulation in cancer cells, but also its toxicity only upon 
light irradiation. That is why it is important to study the PSs toxicity in the absence 
and presence of light irradiation. 
After PSs incubation, cells were washed with PBS and then it was added 100 
µL of RPMI medium to cover the cells. In a dark room, cells were irradiated during 
40 min with red light at a potency of 2.5 mW.cm-2. After irradiation, cells were 
incubated in the humidified incubator gassed with 5% CO2 and 95% air. 
 
3.2.6 Cell viability assay 
 
To evaluate the toxicity and phototoxicity of the PSs the MTT assay was 
used. In living cells, MTT is reduced by the mitochondrial enzyme succinate 
dehydrogenase to the insoluble blue purple formazan crystals, which means that it 
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is possible to correlate the reduction of MTT with this enzyme activity and therefore 
with the cellular viability (124). 
UM-UC-3 cells were plated before at a density of 3 x 104 cells per well, in 96-
wells culture plates for 24 h before treatment and then were treated with the PSs. 
The photodynamic treatment was performed and after 24 h, 50 µL of the medium 
was removed and 10 µL of MTT stock solution (3 mg.mL-1 in PBS buffer) was added 
to each well in order to obtain a final concentration of 0.5 mg.mL-1. The plates were 
then incubated at 37 ºC with 5% CO2 and 95% air for 3 h. After that, the formed 
purple crystals were dissolved by the addition of 150 µL of acidic isopropanol (0.04 
M HCl in absolute isopropanol), with repeated pipetting. The absorbance was 
measured at 570 nm (using 620 nm as the background wavelength), using a plate 
reader spectrophotometer: Absorbance 570 nm – Absorbance 620 nm. The 
percentage of absorbance for each treated sample was normalized to each 
untreated control cells (cells incubated with only PBS): 
 
𝑀𝑇𝑇 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 (%) =  
𝐴𝑏𝑠 (𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒𝑠)
𝐴𝑏𝑠 (𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒𝑠)
× 100 
 
3.2.7 Intracellular levels of Reactive Oxygen Species after PDT 
 
The ROS generation after PDT were detected using three different probes: 
H2DCFDA (118), DHE (119) and MitoPy1 (120), by fluorescence spectroscopy 
technique. H2DCFDA is able to cross the cell membrane and intracellular esterases 
remove its acetate groups, producing H2DCF that will react with several cytotoxic 
ROS and form DCF which fluorescence intensity can be measured and be directly 
correlated with the intracellular ROS levels. DHE probe has blue fluorescence and 
it diffuses across cell membrane. O2·⁻ anions oxidize DHE to ethidium, which 
intercalates within the cell’s DNA, staining the nucleus with bright red fluorescence. 
MitoPy1 probe selectively tracks to the mitochondria and responds to local fluxes of 
H2O2 with a turn-on fluorescence increase. 
 UM-UC-3 cells were plated in 96-wells black plates for 24 h before treatment. 
After photodynamic treatment and washing, cells were incubated with 5 µM of the 
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three probes, under dark conditions, for 1 h at 37ºC. After incubation, cells were 
washed with PBS and mechanically scrapped in 1% (m/v) SDS solution in PBS (pH 
7.0). Then, the intracellular fluorescence was measured with excitation and 
emission filters of 485/20 and 590/35 nm for H2DCFDA, 485/20 and 528/20 nm for 
DHE and MitoPy1. Protein concentration was determined using the Pierce® BCA 
Protein Assay Kit as described previously. 
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